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Nipah virus is a zoonotic pathogen that infects a wide species range including
humans. It was first discovered in Malaysia in 1998 during a large outbreak, but since has
spread to Bangladesh and India causing almost yearly outbreaks in the region since 2001.
The distinct geographic locations have led to two genetically varied strains. Infection of
humans by Nipah virus leads to respiratory distress and acute encephalitis. Pathology
caused by the virus is characterized by vasculitis, necrosis, and edema of small vessels of
the lung and brain primarily. This work investigates differences of pathology and clinical
signs in the hamster model between strains, aiming to explain differences seen in
epidemiology reports. We also characterize infection of endothelial and smooth muscle
cells, which make up the vasculature, and how they react to infection. After better
understanding the pathology in vivo and in vitro, we developed and efficacy tested a
single-dose Vesicular stomatitis virus based vaccine. Data from this work demonstrates
that although the Bangladesh strain is delayed 2 days compared to the Malaysian strain
they cause similar pathology in hamsters. We also show that Nipah virus replicated in
smooth muscle cells but does not cause adverse effects. Finally this study presents a
vaccine that is protective against Nipah virus pathology. Overall this work allows for
future studies using the Bangladesh strain, better defines infection of primary vascular
cells, and proposes a possible vaccine candidate for outbreak use.
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CHAPTER 1 INTRODUCTION
Henipavirus

The family Paramyxoviridae of the order Mononegavirales consists two
subfamilies Paramyxovirinae and Pneumovirinae. Paramyxovirinae include four genera,
Respirovirus, Morbillivirus, Henipavirus, and Rubulavirus (1). Members of this family
are enveloped negative- sense single stranded RNA viruses that cause disease in
vertebrates. Hendra virus, Cedar virus and Nipah virus are part of the genus Henipavirus.
Hendra virus and Nipah virus are highly virulent zoonotic pathogens. Cedar virus is
newly discovered and is yet to be only found in the bat reservoir (2). These viruses are
classified as select agents and must be worked with under biosafety level 4 conditions.
They are pleomorphic in structure varying in size from 180- 1900nm, averaging 500nm
(Figure	
  1-‐1c), making them longer than other paromyxovirses (3). Like other
Paramyxoviruses, Henipaviruses, code 6 genes in a non-segmented genome as seen in
Figure	
  1-‐1a. The genes encoded from 3’ to 5’ are the nucelocapsid (N), phosphoprotein
(P), matrix (M), fusion (F), glycoprotein (G), and the large polymerase (L). The genomes
of Nipah virus and Hendra virus are longer than those of the other paromyxoviruses being
18,246 and 18,234 nucleotides respectively but share a high sequence homology (4, 5).
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Figure	
  1-‐1:	
  Schematic	
  representation	
  and	
  electron	
  micrograph	
  of	
  Nipah	
  virus.	
  	
  
(A) Schematic retranslation of Niaph virus genome. Arrows represent open reading
frames encoding the nucleocapsid protein (N), phosphoprotein (P), matrix protein (M),
fusion protein (F), glycoprotein or attachment protein (G) and large protein (L) or RNA
polymerase. (B) Representation of Niaph virus structure. The RNP complex is located in
the center of the virus shown in red, purple, and green with the virion RNA in black. The
matrix protein (dark blue) makes up virion architecture, underlying the viral envelope.
The surface of the virion is covered with the attachment glycoprotein in light blue and the
fusion protein in yellow. (C) Electron micrograph of Niaph virus budding from a cell.
Micrograph reprinted with permission from Lippincott Williams (6). Copyright © 2013,
Lippincott Williams, a Wolters Kluwer business
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Nipah Virus Replication Cycle
Receptor binding and fusion
The receptor for Nipah virus was identified as the receptor tyrosine kinase, ephrin
B2 (7, 8). Ephrin is a type I transmembrane protein that is the ligand for EphB4/B2.
Ephrins are highly conserved ligands that function in cell-to-cell interactions, signaling,
angiogenesis and neuronal axon guidance (9–11). Eprhrin B2 is expressed on vascular
endothelial cells, with high expression in the lung and brain. Ephrin B3 expression is
limited to the CNS and heart. Ephrin B2/B3 expression is consistent with Nipah virus
tropism (7, 8, 10, 12, 13). Nipah virus was found to have high affinity for ephrin B2 with
slightly less affinity for ephrin B3 (12, 14). Nipah virus has two surface proteins: the
glycoprotein (G) and fusion (F) protein. G functions as the attachment protein binding
ephrin B2/B3. G binding to its receptor triggers F, which acts to fuse the virus to the cell
membrane independent of pH. However there is some evidence that macropinocytosis
could also aid in cell entry (13).
Replication
Once the virus has fused with the cell membrane the ribonucleocapsid enters the
cytoplasm of the cell and the viral mRNA acts as the template starting transcription
(Figure	
  1-‐2) (15). Transcription is initiated at the promoter region in the 3’ UTR. Each of
the 6 genes have individual start and stop sequences with intergenic regions between
genes (1). The Nipah genome only has one promoter thus if the polymerase complex
(P/L) falls off the template re-initiation will only occur at the 3’UTR, this results in a
differential gradient of transcription. This means that transcripts closer to the 3’ end will
be more abundant than ones towards the 5’ end (16). This process results in accumulation
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of viral proteins in the cytoplasm. After accumulation of unassembled nucleocapsid
protein, replication of the genome begins producing a full-length (+) sense anti-genome,
which is the template for the new (–) sense RNA (6). Once completed genomes are
encapsidated by the nucleoprotein forming the ribonucleoprotein (RNP).
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Figure	
  1-‐2:	
  Replication	
  schematic	
  of	
  paramyxovirus	
  life	
  cycle.	
  	
  
An incoming virion fuses with the plasma membrane and releases the RNP into the
cytoplasm. mRNA is represented by solid lines with closed circles at the 5’ end and An
representing the 3’ poly A tail. Dotted lines represent intracellular transport. Reprinted
with permission from Lippincott Williams (6). Copyright © 2013, Lippincott Williams, a
Wolters Kluwer business.
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Budding and egress
Both glycoproteins are processed after translation, prior to their association with
the membrane for incorporation into a new virion. G is synthesized in the endoplasmic
reticulum (ER) then matured through the golgi, eventually trafficking to the cell
membrane. F is also synthesized transported to the ER as an inactive precursor that is
proteolytically activated in the trans-Golgi network then trafficked to the plasma
membrane (6, 17, 18). Nipah budding is thought to be triggered by the accumulation of
matrix protein; matrix protein alone can produce virus like particles (19). The matrix
protein is trafficked to the nucleus for post-translational modification then returns to the
membrane to bridge the glycoproteins in the membrane with the RNPs (6, 20). In Nipah
replication, viral proteins associate with specific sites on the host cell membrane, where
they pinch off and result in a virion with an envelope containing host-derived membrane
that contains viral glycoproteins encapsulating matrix proteins and RNPs (15).
Nipah Virus Epidemiology
Discovery of Nipah virus
Malaysian outbreak
In 1998 there was an outbreak of respiratory sickness in swine in Malaysia. Soon
after the agent jumped to the pig handlers causing similar respiratory symptoms as well
as encephalitis. The outbreak originated in Northwestern peninsular Malaysia but quickly
spread into the south as well as into Singapore (through pig exportation) (21, 22). At first
the outbreak was misdiagnosed as Japanese encephalitis virus, which is endemic in rural
Malaysia (23). The outbreak continued into 1999 infecting more than 250 humans with
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over 100 fatalities (24). In mid-March 1999 the causative agent was identified as a
Hendra-like virus and subsequently named Nipah virus after the home village of the
patient the virus was isolated from (4, 25–27). Later sequencing of Nipah virus isolates
showed that pig and human isolates are very similar thus the outbreak could have been
caused by as little as 1 or 2 introductions (28, 29). Retrospectively, it is thought that
Nipah virus may have emerged as early as 1997, when unexplained small scale pig deaths
were reported as well as 6 causes of encephalitis that later tested positive for Nipah
specific IgG (21).
The risk factors associated with this outbreak focused on direct contact or close
proximity to pig or pig secretions (30, 31). This led to quarantining infected pig farms,
evacuating people out of infected areas and public announcements about how to properly
protect yourself when dealing with swine (23). Eventual containment of the outbreak was
brought about by culling of over a million pigs in the infected areas as well as the
discontinuing exportation until the outbreak subsided (22, 26, 31). These precautions
eventually led to the end of the outbreak.
Bangladesh outbreaks
After the initial outbreak ending in 1999 Nipah virus was dormant in the human
population until 2001 when it emerged on the Indian subcontinent. Since the first
outbreak there have been almost annual small-scale outbreaks occurring in Bangladesh
and India. Even though positive serology was identified no virus was isolated from the
Bangladesh/ India outbreaks until 2004 when it was confirmed to be Nipah virus (32).
Differing from the Malaysian outbreak, the Bangladesh outbreaks are small, still
occurring, and do not involve pig farms. Bangladesh lacks large-scale pig farms, instead
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individual families may have a small number of various species of animals. Sequencing
of virus isolates from the numerous outbreaks have shown over 23 individual
introductions with higher variation than the Malaysian isolates (33). In comparing the
Bangladesh outbreaks over time it appears that the average case fatality is 70% (33).
Another difference between the Malaysia and Bangladesh Nipah virus is that the
Bangladesh outbreaks support human to human transmission with about 7% of
individuals spreading disease to a median of 7 people (33).
Animal hosts
Natural animal hosts
During the Malaysian outbreak field investigations looking for an animal host
were initiated. Due to its similarities with Hendra virus fruit bats of the family Pteropus
were heavily focused on as a possible natural reservoir. In a study done in 2001 collecting
blood for serologic data Yob et al. found a prevalence of 25% in fruit bats in Malaysia
but no virus was isolated (34). Urine and fecal samples were also collected for sampling
of Nipah virus in hopes of isolating virus (35). Nipah virus was later isolated from pooled
urine (36). It was also demonstrated that bats intermediately shed virus even though they
show no signs of disease (37, 38). Further study of Pteropus bats have shown henipavirus
positive bats in Malaysia, Cambodia, Bangladesh, and Africa following the bats
geographic range, suggesting the possibility of spread of the virus outside current
endemic areas (34, 39–42).
As previously stated pigs played a large role in the Malaysian outbreak. Once
Nipah virus entered a large pig farm the virus spread rapidly with a close to 100%
infection rate. Incubation in these animals was 7-14 days and mortality was between 5	
  

8	
  

15% (43). If signs of disease were seen they included neurologic signs in older pigs as
well as increased abortions and respiratory signs in younger pigs. Other domestic animals
tested positive in Malaysia but none as high in prevalence as pigs and bats. It is believed
that theses animals, which include dogs, cats, and goats, became infected from pigs or
bats and were dead end hosts (26, 34, 43, 44). Differing from the Malaysian outbreak
there is thought to be no intermediate host during Nipah Bangladesh outbreaks.
Experimental animal models
Experimentally various species have been identified to support Nipah virus
infection, replication, and disease. Guinea pigs were examined as a model and support
viral replication; however, in general clinical presentation seemed to be mild to
asymptomatic but death can occur (45). Infection in guinea pigs causes systemic vascular
disease, fever, weight loss, and twitching. Another animal model for Nipah virus is the
cat. This model mimics human disease showing signs of respiratory distress including
fever and elevated respiratory rate, however there is no evidence of encephalitis in cats
(46, 47). Cats present with clinical signs from day 4 to 8 with systemic vascular disease
leading to death. Pigs have been infected experimentally and disease is similar to that
which is seen with natural infection with high morbidity and low mortality (46, 48).
However, like natural infection, experimentally some pigs are asymptomatic. If pigs do
develop signs of infection it is often age dependent with older animals having neurologic
signs and respiratory distress in younger animals (43, 46, 49).
The three animal models used the most in Nipah virus research include hamsters,
ferrets, and nonhuman primates. Hamsters are a small animal model that mostly
recapitulates human disease. These animals have clinical signs of both respiratory disease
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as well as neurologic involvement (50) Hamsters have systemic vasculitits with
pathology of the lung and brain often leading to death. Viral shedding is detectable and
transmission is possible (51, 52). In the hamster model dose and route of infection affect
disease outcome; low dose infections end in encephalitis around day 12 post challenge
while high does infections are more respiratory and animals start to die around day 5 post
challenge (53). Anther animal model that displays both respiratory and neurologic signs
is the ferret. Infected ferrets present between days 6-10 post challenge with cough,
depression, nasal discharge, and hind limb paralysis (54). Viral shedding does occur and
disease is lethal. Another animal model for Nipah disease is the nonhuman primate. Both
squirrel monkeys and African green monkeys have been infected and show clinical
disease. Squirrel monkeys only show mild clinical diseases in about half of challenged
individuals but infection can be lethal (55). The nonhuman primate model that more
closely resembles human disease is the African green monkey. This model is close to
human disease presenting with both respiratory ad neurologic symptoms about 7 days
post challenge (56). This model is mostly lethal at high doses and characterized by
pathology of the lung and brain, frothy discharge, viral shedding and endothelial
syncytia.
Transmission
Transmission of Nipah virus Malaysia strain is thought to have occurred from bat
to pig to human, mainly focusing on oral and urogenital secretions from pigs as the route
of transmission (23, 30, 57). This transmission route is supported by the fact that
educating people about proper personal protective equipment as well as culling pigs led
to the end of the outbreak (26). There has however been some evidence that suggests
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there could have been a few cases of infection passed from patient to healthcare worker.
In a serologic study in Malaysia of 363 healthcare workers from hospitals that handled
most Nipah patients, only 3 had positive Nipah IgG titers with no IgM or neutralization
detectable (58). All 3 nurses described caring for Nipah infected patients for over a
month. Of these 3, 2 described mild febrile illness prior to blood sampling. Another study
also found 1 asymptomatic nurse with antibodies positive for Nipah (59). The finding of
4 health care workers with antibodies against Nipah virus suggests that person-to-person
transmission may have occurred in Malaysia.
In the Bangladesh outbreaks it is thought that the virus is spread from bats to
humans from drinking raw date palm sap or coming in direct contact with bat secretions
(41, 60). One of the reasons that date palm sap is a possible transmission route is that
Nipah virus outbreaks in Bangladesh coincide with the date palm harvest season, late
December to early April (33). At this time, bark is shaved off the tree and a tap is inserted
allowing sap to drip into open pots. Pots are collected daily and sap is sold for immediate
consumption (raw) as well as processing into molasses (61, 62). Reports of bats visiting
sap harvest locations were confirmed by infrared photography, which documented 185
bat visits in 20 nights with 84% of the bats directly contacting the sap (41). In case
studies it has been found that there is a higher reporting prevalence of infected
individuals having contact with or drinking raw date palm sap than not (63). However,
Nipah virus has not been isolated from date palm sap. Several experimental studies have
shown that Nipah virus is recoverable from various juices (mirroring fruit dropped from
bats) and artificial date palm sap days after being spiked with virus (52, 64).
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Also differing from the Malaysian outbreak, transmission in Bangladesh has been
attributed to person-to-person contact (44, 65–67). In reviewing cases between 20012007 in Bangladesh, Luby et al. found that out of 122 patients questioned 51% became
sick after having direct contact with an infected patient 5-15 days earlier (33). Human to
human spread of virus is thought to be attributed to respiratory droplets released during
coughing fits. In a later study it was identified that 7% of cases transmit infection, most
often to health care workers or family members (68). Two outbreaks, one in 2001 in India
and one in 2004 in Fardpur supported the largest number of person-to-person
transmission as well as spaned up to 5 generations of person-to-person transmission (67,
69). There has also been documentation of corpse-to-human transmission of the virus
(70). A few studies suggest nosocomial transmission and in one study swabs were taken
of the walls and bed frame of a patients room and found to be positive 5 weeks after
death, supporting environmental stability and nosocomial transmission (58, 67, 70, 71).
Experimentally, the Bangladesh strain of Nipah virus has been identified in respiratory
secretions and oral/ nasal swabs and has been documented to be transmitted by direct
contact and, not as efficiently, by fomite in the hamster model (51, 72). Together these
data support a more efficient person-to-person transmission of the Bangladesh strain over
the Malaysian, with the lack of an intermediate host identified in Bangladesh.
Human disease
Clinical manifestations
Incubation periods for Nipah virus is estimated to be 4-45 days with most
incubation periods lasting 2 weeks (73, 74)The average duration of illness in humans for
Nipah virus is around 9 days (from fever to death) but has lasted anywhere from 2-30
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days with some patients recovering (75). The age range of infected individuals is a large
spread, 2-75 years, with variations in average age between outbreaks, most often middle
age individuals are infected (73, 75, 76). In the case of the Malaysian outbreak the male
to female ratio was highly skewed towards males, however this could be attributed to the
route of infection and the male prevalence in pig handling (75). The male to female
proportion throughout the Bangladesh outbreaks are still male skewed but are close to
50/50 (67, 73). Generally Nipah virus symptoms fit under two categories: respiratory
distress or acute encephalitis. Major clinical symptoms of Nipah virus infection in
humans are listed in Table	
  1-‐1. Generally, patients present with flu like symptoms
including fever, headache, drowsiness, myalgia, and dizziness (73, 74). Other
manifestations of Nipah virus infection include are flexia, fast resting heartbeat, high
blood pressure, segmental myoclonus, and doll eye syndrome (6). The Malaysian strain
of the virus had higher prevalence of acute encephalitis than the Bangladesh isolate (74).
Neurologic symptoms are paired with MRI results of disseminated small discrete lesions
in the white matter and to lesser extent the gray matter (74, 76, 77). Respiratory distress
is characterized by difficulty breathing, coughing, shortness of breath, and atypical
pneumonia (73).
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Table	
  1-‐1:	
  Common	
  clinical	
  symptoms	
  and	
  other	
  features	
  of	
  Nipah	
  virus	
  
infection.	
  
General
fever
headache
dizziness
myalgia
severe weakness
vomiting
diarrhea

	
  

Respiratory
cough
shortness of breath
respiratory difficulty
abnormal chest radiographs
Interstitial pneumonia
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Neurologic
convulsions
abnormal reflex
altered mental status
unconsciousness
elevated lymphocytes in CSF
Elevated protein in CSF
lesions in white and gray matter

Both outbreaks support relapsing encephalitis, often occurring in people with a
primary infection that was acute or asymptomatic. Late-onset or relapsing infection can
occur anytime from months to years later and is often associated with neurological sequel
(74, 76, 78, 79). About 10% of survivors experience relapse but it is speculated that this
could be an underestimate (79). Magnetic resonance imaging (MRI) findings from
relapsing patients often showed a change from discrete small legions to more confluent
wide spread lesions (74). Symptoms associated as high risk factors for a poor outcome
are brain stem involvement, virus in the cerebrospinal fluid (CSF), and seizures (24, 74).
Pathology
Most of what we know about human pathology comes from the Malaysian
outbreak, where necropsies were more common. Common pathologic findings central to
disease include systemic vasculitis, endothelial destruction, and CNS involvement (76,
80). Specifically, Nipah virus pathology affects blood vessels of the CNS, lung, heart,
and kidney. Typically small vessels (e.g. capillaries, venules) showed vasculitis, while
medium to large vessels remained uninfected (75, 77). Vasculitis is characterized by
destruction of the endothelium, mural fibroid necrosis and karyorrhexis (Figure	
  1-‐3).
There are also reports of inflammatory infiltration, thrombosis, necrosis, and
hemorrhaging in infected vessels. In some cases giant multinucleated syncytia, are seen
in vessel walls and endothelial cells throughout infected organs. Syncytia formation is
more prevalent in cases were duration of illness lasts from 6-15 days (75).
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Figure	
  1-‐3:	
  Cartoon	
  representation	
  of	
  pathology	
  caused	
  by	
  Niaph	
  virus	
  
infection.	
  	
  
The major organs affected by Nipah virus pathology include the brain, lung and spleen.
The images on the right are from the organs of experimentally infected animals showing
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a representation of classic Nipah virus pathology. Vasculitis is central to infection and is
characterized by edema, fibrin, perivascular inflammation, and endothelial syncytia.
The main infection induced pathology findings are in the CNS, paricularly brain.
Again, vascular induced thrombosis was observed along with parenchymal necrosis.
There are also appearances of some viral inclusions throughout both the white and gray
matter. Matching MRI findings taken during infection, necrotic legions or plaques were
observed with microcystic degeneration, microinfractions, and perivascular cuffing (75,
77, 80). Immunohistochemistry (IHC) staining of the CNS showed Nipah positive
antigen staining in blood vessels as well as neurons that are associated with vasculitis or
necrotic plaques (75). There is also positive staining in viral inclusions.
Other organs are also affected during infection. The lung is the next location of
prominent virus induced pathology. Findings of vasculitis and necrosis are associated
with small blood vessels. Syncytial cells are observed in alveolar spaces along with
hemorrhaging causing pulmonary edema (75). Besides the lung and CNS pathology is
observed in the spleen, lymph nodes, kidney and heart. Pathology documented in these
organs consisted of vasculitis, fibroid necrosis, and some hemorrhaging (75). IHC
staining for Nipah virus in these organs mainly focuses around blood vessels. Specifically
in the endothelium and tunica media (smooth muscle cells surrounding vessels) (75).
Pathology of late-onset encephalitis differs significantly from acute pathology. In
the case of late-onset encephalitis the few necropsies performed show no vasculitis in any
organ (81). Pathology in the CNS is more predominant and disseminated compared to
acute encephalitic patients (78, 81). The viral inclusions in relapse patients are larger and
more extensive. Lesions of the parenchymal are more confluent and larger causing
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neuronal loss and gliosis (59). Also differing from acute infection peracymal cuffing is
limited and necrotic plaques are not found (75). Viral staining of these patients
demonstrate prominent glial and neuronal staining that are more diffuse than acute
patients with no blood vessel staining (75).
Cell tropism
Nipah virus pathologic features can be attributed to the tropism of Nipah virus.
Nipah virus cell tropism is linked directly to receptor expression. Ephrin B2 and B3 are
the receptors of the virus associating with the G of the virus. Ephrin B2 is found on
arterial endothelial cells, smooth muscle cells, as well as neurons while ephrin B3 is more
closely associated with the brain stem (10, 17). Ephrin expression levels vary in different
organs and thus regulates Nipah virus infection (10). Ephrins are very conserved proteins,
which probably accounts for the wide species range of Nipah virus (82). In cell culture,
permissiveness of cells to Nipah virus has been linked to ephrin expression, however few
cases of non-ephrin binding have been observed as well as the involvement of
macropinocytosis (13, 82, 83). In general the virus favors vascular tropism, infecting
endothelial cells and the tunic media as well as neuronal cells (80). Major organ and cell
types found to be involved during Nipah virus infection are summarized in Table	
  1-‐2
(17).
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Table	
  1-‐2:	
  Organ	
  and	
  cells	
  tropism	
  of	
  Nipah	
  virus	
  infection	
  in	
  Humans.	
  	
  
	
  
Organ
Brain

Lung

Spleen
Kidney
Heart

	
  

cell types infected
endothelial cells
tunica media
neurons
rare- glical cells, ependyma
endothelial cells
tunica media
rare- bronchiolar epithelium
Periarteriolar sheath cells
macrophages
endothelial cells
tunica media
endothelial cells
tunica media
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Treatment and Prevention
Treatment
Since the discovery of Nipah virus there have been numerous attempts to discover
a treatment for infection (Table	
  1-‐3). At the time of the Malaysian outbreak Ribavirin, a
nucleoside inhibitor used to stop viral RNA synthesis, was made available to patients;
this antiviral has been shown to be effective against other RNA viruses including
Respiratory syncytial virus (84). The drug was given to 140 patients with 54 patients
acting as controls. Patients in the Ribavirin group had a mortality rate of 32% compared
to 54% in the control group, hospital stay and time on a ventilation system were also
shorter in the treated group (85, 86). In an experimental setting Ribavirin limits
replication in vitro (87–89). However, when Ribavirin was tested in the hamster model
against Nipah virus, alone and in combination with Chloroquine, protection was not
afforded (90, 91). Ribavirin was also evaluated in the African green monkey as a
treatment option against Hendra virus and found to increase time to death, but not
decrease mortality skewing disease to encephalitis over respiratory signs (92). Currently,
Ribavirin is not used as a treatment option against Nipah virus.
Another treatment option proposed for Nipah virus are fusion inhibitory peptides.
The peptides act to blocking fusion of the F protein with the cellular membrane. By using
the conserved heptad repeat region in the fusion protein of Hendra virus, Nipah virus, or
human parainfluenza virus 3 researchers have been able to reduce cell fusion in tissue
culture as well as show plaque reduction against live Nipah virus (93–97). It is proposed
that the fusion inhibitory peptides act after the fusion protein undergoes conformational
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changes inhibiting its structural formation into a 6-helix coiled coil bundle, which is
needed for fusion (97, 98).
Another strategy under development as a treatment against Nipah virus is
antibodies. Early studies showed that passive transfer of polyclonal sera from vaccinated
hamsters could be used to prevent death in naive hamsters given before Nipah virus
challenge (99). Evolution of antibody therapy against Nipah virus focuses on monoclonal
antibody development. First attempts used murine derived antibodies against NiV-F or
NiV-G. Both F and G derived antibodies protected hamsters before challenge. The
antibody against NiV-F protected100% of animals 1 hour after challenge and 50% if
administered 24 or 48 hours after while the NiV-G antibody only protected 50% 1 hour
after (100).
Next generation antibodies came from using a peptide display library and a
human monoclonal antibody that could neutralize both Hendra and Nipah viruses (101).
This antibody, m102.4, was then fully matured creating a full length human IgG antibody
that is fully cross neutralizing against both viruses (102). This antibody was tested post
challenge in the ferret model (Nipah virus challenge) and the African green monkey
(AGM) model (Hendra virus challenge) and was found to be protective (54, 103). In
ferrets the antibody was given 10 hours post challenge and showed protection (54). In
the AGM m102.4 was given 10, 24, or 72 hours after challenge and again 48 hours after
the first dose resulting in complete protection (103, 104).
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Table	
  1-‐3:	
  Treatments	
  tested	
  against	
  Nipah	
  virus	
  infection.	
  	
  
Treatment

in vitro

Ribavirin

Cell culture

Species
•
Human

•

Hamster
NHP

•
•
•

Sera transfer

Hamster

•
•
•

Murine antibody
Humanized antibody
m102.4

Hamster

• Protection

Inhibitory peptides

Cell culture

Cell culture

• Neutralization
Ferret
NHP

	
  

Efficacy
Reduced
replication
Reduced
mortality
None
None
Encephalitis
skewed
Reduced fusion
Reduced plaques
Protection
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• Protection
• Protection

Reference
(87–89)
(85, 86)
(90, 91)
(92)
(93–97)
(99)
(100)
(101, 102)
(54)
(103)

Vaccines
As early as 2004 possible vaccine candidates were starting to be developed
against Nipah virus infection (Table	
  1-‐4). Approaches focused on the surface
glycoproteins G and F of Nipah virus. Due to biocontainment requirements some vaccine
studies were performed without challenge. This study measured immune response to
infection rather than efficacy. One such study was used a recombinant Newcastle disease
virus expressing F or G as a vaccine vector. This vector was tested in mice and pigs using
a prime boost strategy (105). Both vectors produced an antibody response as well as
demonstrated neutralization suggesting the possibility of protection; however, animals in
this study were never challenged. Another approach at protecting against Nipah virus
disease focused on Venezuelan equine encephalitis replicon particles encoding G or F
from Nipah virus (106). This vaccine was administered in 3 doses to mice and produced
antibodies and neutralizing antibodies. Virus like particles (VLP) were also tested as a
possible vaccine. This multi-dose vaccine was produced by expressing Nipah virus M, G,
and F. The particles were fusogenic in nature and looked like wild type virions by
electron microscopy. Antibody production and neutralization were measured after mice
were immunized 3 times.
The next batch of vaccine candidates were tested in the hamster model testing for
both immune response and efficacy. A DNA vaccine in two doses using codon optimized
Nipah F or G in expression plasmid pCAGGS was perfrmed in mice (107). The presence
of antibodies and neutralizing antibodies were used to support the possibility of efficacy.
In a study using the hamster model, this approach did not protect animals from lethal
Nipah virus challenge (DeBuysscher et. al, unpublished). Another candidate was created

	
  

23	
  

using Vaccinia virus recombinants expressing Nipah virus G or F as well as a coimmunization with both F and G constructs in a prime boost strategy (99). Hamsters had
high levels of neutralizing and non-neutralizing antibodies and were protected from
infection with no detectable virus after challenge. This study also completed a passive
transfer of sera from vaccinated hamsters to naïve animals; again protecting 100% of
animals from disease, suggestion antibodies were important for protection. One of few
single dose vaccines candidates include an adeno- associated virus (AAV) expressing G
(108). This vector was tested in hamsters with 100% protection. After vaccination
neutralizing antibodies were measured.
Another disease model used in some studies to test efficacy is the pig, which is
the intermediate Nipah virus host. A recombinant Canarypox virus expressing F or G and
was tested with a prime boost vaccination schedule (49). Vaccinated pigs were protected,
having no evidence of viral shedding, only low levels of Nipah RNA were detected in the
olfactory bulb, trigeminal ganglion, and trachea, however no virus was isolated and there
was little pathology compared to controls. This vaccine also produced neutralizing
antibodies. Other large animal model for Nipah infection that has been used for vaccine
efficacy testing is the cat and ferret. A recombinant soluble glycoprotein (sG) of Nipah or
Hendra viruses were produced and coupled with CpG and administered in multiple doses
to cats and ferrets to test the efficacy (109–111). These studies found that the sG from
Hendra virus was more cross-reactive, thus this antigen was focused on. Immunization
with sG is thought to block receptor and to produce high levels of neutralizing antibodies.
Ferrets challenged 20 days after immunization or 12 months after immunization were
protected from disease (111). Two separate studies propose a non-replication
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recombinant Vesicular stomatitis virus (rVSV) as a vector for Nipah vaccination (112–
114). Both studies use a rVSV lacking its own glycoprotein and coding for Nipah virus F
or G or a single-cycle F and G rVSV. Constructs protect hamsters or ferrets from disease
and reduce virus replication in tissues. The constructs, when administered produce a
strong immune response with neutralizing antibodies.
One vaccine was tested in the African green monkey model of Nipah virus
infection. This vaccine was administered in multiple doses with a vector based on a
measles recombinant system expressing Nipah G (115). This vaccine was tested in
hamsters and African green monkeys in 2 doses and demonstrated protection against
lethal outcome and disease.
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Table	
  1-‐4:	
  Vaccine	
  candidates	
  against	
  Nipah	
  virus	
  infection.	
  

Vaccine platform Species

Vaccine schedule

Nipah virus
challenge dose
(route)

Efficacy

Ref.

Newcastle virus
expressing either F
or G

Mice
Pigs

Prime with 1 boost

N/A

• T-cell
response
• Neutralizing
antibodies
• Long lasting

Venezuelan equine
encephalitis virus
expressing G or F

Mice

Prime with 2 boosts

NA

• Neutralizing
antibodies

(106)

VLPs comprised
of G, F and M

Mice

Prime with 2 boosts

NA

• Neutralizing
antibodies

(116)

NA

• Neutralizing
antibodies
• No protection
in hamsters

(107)

DNA vaccination
Mice
(pCAGGS G or F) Hamsters

	
  

Prime with 1 boost
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(105)

Vaccinia virus
(VV) expressing G Hamster
and/or F

Prime with 1 boost

• Protection
• Passive
antibodyprotects

(99)

• 100% Nipah
Adeno associated
Mice
1e4 PFU, Nipah or • 50% Hendra
virus (AAV)
Single immunization
Hamster
Hendra
• Antibodies in
expressing G
mice

(108)

• Reduction in
virus
• Inhibition of
viral shedding

(49)

Recombinant
canarypox virus
expressing G or F

Soluble Nipah or
Hendra G

Pigs

Cats
ferrets

Prime with boost

Prime with boost
Prime with 2 boosts

Recombinant
vesicular
Mice
stomatitis virus Hamsters Single immunization
(VSV) expressing Ferrets
G or F

Recombinant
measles virus
expressing G

	
  

1x103 PFU
(intraperitoneal)

Hamster
NHP

Prime with 1 boost
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2.5x105 PFU
(intranasal)

5x104 TCID50
(oronasal)
2

5x10 TCID50
(subcu.)

N/A

N/A

• Protection
• Non-sterile
immunity

(109–
111)

• Neutralizing
antibodies
• Protection in
hamsters

(112–
114)

• Protection in
hamsters
• No clinical
signs in NHP

(115)

CHAPTER 2 AIMS
Goal: To understand pathogenesis of Nipah virus and to create a vaccine to protect
against Nipah virus infection and disease.
Specific Aim 1: Comparison of the pathogenicity of Nipah virus isolates from
Bangladesh and Malaysia in the Syrian hamster.
We hypothesize that infection and disease caused by Nipah Bangladesh will be
more severe that Nipah Malaysia. In this aim we will establish the hamster as a model for
Nipah Bangladesh as well as compare infection and pathogenicity of Nipah Bangladesh
and Nipah Malaysia.
Specific Aim 2: Defining the mechanisms of pathogenicity of Nipah virus in smooth
muscle and endothelial cells.
We hypothesized that Nipah virus infects and replicates in endothelial and smooth
muscle cells, leading to viral pathogenesis and cell destruction. In this aim we plan to
further characterize the role of these two important cell types for Nipah infection and
pathogenicity both in vivo and in vitro.
Specific Aim 3: Development and characterization of a recombinant vesicular
stomatitis virus based Nipah vaccine.
We hypothesize that a replicating recombinant vesicular stomatitis virus based
vector expressing Nipah proteins (antigens) is an effective vaccine candidate. In this aim
we will use the hamster model to test the immunogenicity and efficacy of a new Nipah
vaccine candidate.
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CHAPTER 3 COMPARISON OF THE PATHOGENICITY OF NIPAH VIRUS
ISOLATES FROM BANGLADESH AND MALAYSIA IN THE SYRIAN
HAMSTER
Abstract
Nipah virus is a zoonotic pathogen that causes severe disease in humans. The
mechanisms of pathogenesis are not well described. The first Nipah virus outbreak
occurred in Malaysia, where human disease had a strong neurological component.
Subsequent outbreaks have occurred in Bangladesh and India and transmission and
disease processes in these outbreaks appear to be different from those of the Malaysian
outbreak. Until this point, virtually all Nipah virus studies in vitro and in vivo, including
vaccine and pathogenesis studies, have utilized a virus isolate from the original
Malaysian outbreak (NiV-M). To investigate potential differences between NiV-M and a
Nipah virus isolate from Bangladesh (NiV-B), we compared NiV-M and NiV-B infection
in vitro and in vivo. In hamster kidney cells, NiV-M-infection resulted in extensive
syncytia formation and cytopathic effects, whereas NiV-B-infection resulted in little to no
morphological changes. In vivo, NiV-M-infected Syrian hamsters had accelerated virus
replication, pathology and death when compared to NiV-B-infected animals. NiV-M
infection also resulted in the activation of host immune response genes at an earlier time
point. Pathogenicity was not only a result of direct effects of virus replication, but likely
also had an immunopathogenic component. The differences observed between NiV-M
and NiV-B pathogeneis in hamsters may relate to differences observed in human cases.
Characterization of the hamster model for NiV-B infection allows for further research of
the strain of Nipah virus responsible for the more recent outbreaks in humans. This model
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can be used to study NiV-B pathogenesis, transmission, and countermeasures that could
be used to control outbreaks.
Author Summary
Nipah virus causes severe disease in humans and outbreaks have occurred in two
geographic regions, Malaysia and Bangladesh, and viruses have been isolated during
outbreaks from both of these regions (NiV-M and NiV-B, respectively). The original
outbreak of Nipah virus occurred in Malaysia and caused severe encephalitis in humans.
All subsequent outbreaks of Nipah virus have occurred in Bangladesh or India and
disease has been characterized as having a strong respiratory component. Nipah virus is a
public health concern that can cause up to 100% lethality in humans and there is no
approved treatment or vaccine. Current research should focus on understanding disease
progression and pathogenicity. We compared NiV-M and NiV-B infection and disease
progression using the Syrian hamster model. We found that NiV-M is more destructive in
cultured hamster cells and has faster onset of cytopathogenicity compared to NiV-B. This
is also true in hamsters, where although both viruses are pathogenic and cause a similar
disease, pathology caused by NiV-M infection is accelerated. These data show that there
is a difference in disease progression between the two strains of Nipah virus and will
allow for a more detailed understanding of the events leading to disease caused by these
viruses.
Introduction
Nipah virus is a member of the family Paramyxoviridae, genus Henipavirus, and
was discovered in 1998–99 to be the etiological agent responsible for an outbreak of
severe respiratory disease in pigs (4) and encephalitis in humans in Malaysia (74). All
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subsequent outbreaks of Nipah virus have occurred in Bangladesh or India, beginning in
2001, and have occurred on an almost annual basis (117). Genetic data demonstrate that
the isolates from Malaysia (NiV-M) and Bangladesh (NiV-B) represent two distinct
Nipah virus strains (28, 117). Nipah virus outbreaks have case fatality rates of up to
100% and there are no approved vaccines or treatments and these viruses have been
categorized as a biosafety level 4 (BSL4) agents. Nipah virus differs from other
paramyxoviruses in its ability to infect a wide range of mammals including bats (36),
dogs (4, 26), horses (118), pigs (4), and cats (4, 80). Wildlife surveillance at the time of
the first outbreaks, along with several subsequent studies, has identified fruit bats of the
family Pteropodidae as the natural reservoir of Nipah virus (32, 34, 36, 119).
During the first Nipah virus outbreak in Malaysia, NiV-M caused over 265 cases
of encephalitis with 105 human deaths, resulting in a case fatality rate of 40% (4).
Common clinical manifestations of Nipah virus infection included fever, headache,
respiratory disease, encephalitis and loss of consciousness (75, 120). Fatal human cases
of NiV-M infection were characterized by pathology involving the respiratory tract,
central nervous system (CNS), heart, kidney and spleen (75). NiV-M infection causes
vasculitis characterized by destruction of the endothelium, syncytia formation,
thrombosis and necrosis, with infiltration of inflammatory cells throughout affected
organs. In the lungs of infected humans, pulmonary edema, alveolar hemorrhage and
pneumonia were documented as well as occasional multinucleated giant cells found in
alveolar space (75). During this outbreak, the disease predominantly affected the nervous
system with prominent signs of brain stem dysfunction. Magnetic resonance imaging of
the brains of infected individuals showed focal lesions throughout the white matter (75).
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In a study examining 94 Nipah virus-infected patients in Malaysia, only 6% showed
abnormal chest radiographs, and of these, only one presented with a cough (74). Also,
cases of late onset or relapsing encephalitis were documented during the Malaysia
outbreak (74). During the Malaysian outbreak, pigs predominantly showed signs of
respiratory disease and were determined to be an intermediate host (24, 27).
Epidemiologically, reports of infection with NiV-B differ from that of NiV-M
infection in several aspects. Clinically, NiV-B infection resulted in a higher percentage of
respiratory disease and a higher case fatality rate, reaching up to 100%, compared to
NiV-M infection (120). This disparity could reflect the differences in availability of
health care and in reporting (73). Disparities, however, could also be caused by intrinsic
differences in the pathogenicity of NiV-M and NiV-B. NiV-B is transmitted from bats to
humans by multiple routes including the ingestion of contaminated date palm sap (60),
and can subsequently be transmitted nosocomially (71), or by human-to-human
transmission (44, 65–67). Common clinical signs and symptoms of NiV-B infection
included fever, altered mental status, headaches, cough, and difficulty breathing (73,
121). During the Bangladeshi outbreaks, acute respiratory distress was noted in many
patients (73, 122). Febrile neurologic illnesses were also documented in some outbreaks
of NiV-B, with lesions found in the gray and white matter of the brain (69, 121, 123). In
one study looking at 92 patients, 69% had difficulty breathing and 62% had a cough (73).
Limited studies have been conducted to describe the pathology in NiV-B infected
patients.
In contrast to most other paramyxoviruses, Nipah virus has a broad species
tropism and there are few suitable animal models that recapitulate human disease.
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Experimentally cats, guinea pigs, ferrets, pigs, non-human primates, and Syrian hamsters
have been shown to support NiV-M viral replication resulting in clinical signs of
infection (47, 56, 124). The Syrian hamster is the only small rodent model that closely
mimics multiple aspects of human disease (47, 48, 50, 80). When infected
intraperitoneally (i.p.) or intranasally (i.n.) with NiV-M, hamsters develop respiratory
disease and/or encephalitis. The pathological changes that occur in the hamster are
similar to those described in humans. The presence of vasculitis, necrosis, and
inflammation is seen in both the human and hamsters. Viral antigen and disease
pathology is observed in lung, kidney and heart tissue (50, 53). Similar to human
infections that lead to encephalitis, hamsters show antigen positive neurons, necrosis, and
vasculitis in the CNS (50). These similarities in infection between humans and hamsters
make the Syrian hamster a suitable model for the study of Nipah virus pathogenesis.
This study was designed to compare NiV-B and NiV-M infections in a hamsterderived cell line, followed by a comparison of the pathogenesis and immune responses to
infection by both virus strains in the Syrian hamster. Our results demonstrated that
hamster cells are permissive for infection by both virus strains, with NiV-M causing
increased syncytia formation and cytopathic effect (CPE) compared to NiV-B. In vivo,
NiV-B infection resulted in a delayed disease progression compared to NiV-M infection.
Overall NiV-M is more cytopathic in vitro and causes an accelerated disease in vivo,
compared to NiV-B.
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Materials and Methods
Ethical statement
All work with Nipah virus, potentially infectious materials, and infected hamsters
was completed in the BSL4 facility at the Rocky Mountain Laboratories, Division of
Intramural Research, National Institute of Allergy and Infectious Diseases, National
Institutes of Health. All standard operating procedures applied were approved by the
Institutional Biosafety Committee (IBC). All animal experiments were approved by the
Institutional Animal Care and Use Committee of the Rocky Mountain Laboratories and
performed following the guidelines of the Association for Assessment and Accreditation
of Laboratory Animal Care, International (AAALAC) by certified staff in an AAALACapproved facility.
Virus propagation
NiV-B and NiV-M were provided by the Special Pathogens Branch of the Center
for Disease Control and Prevention, Atlanta, GA, USA. NiV-M was isolated from a
human case (cerebrum) in 1999 and passaged on Vero E6 cells a total of four times
before used in experiments (125). NiV-B was isolated from a throat swab of a lethal
human infection from Bangladesh in 2004 and passaged in Vero E6 cells a total of three
times (28). Viruses were propagated on Vero E6 cells in Dulbecco's Modified Eagle’s
medium (DMEM) (Sigma) supplemented with 10% fetal calf serum, 2 mM l-glutamine,
50 IU/mL penicillin and 50 µg/mL streptomycin (Life Technologies). Supernatants were
collected and clarified by low-speed centrifugation and stored in liquid nitrogen.

	
  

34	
  

Virus titration
For plaque assays, Vero C1008 (European Collection of Cell Cultures) were
grown to confluency in 6-well plates. Media was replaced with 250 µL of serial 10-fold
dilutions of virus in DMEM and incubated for 1 hr at 37°C, rocking every 15 min. The
virus inoculum was replaced with 2 mL of a 1:1 mixture of 2× minimal essential medium
(MEM) and 1.6% low-melt agarose (Life Technologies). The cells were then incubated
for 3 d at 37°C, 5% CO2 before staining with 2 mL of a 0.25% crystal violet solution in
10% formalin for 3 hr at room temperature. The stain and overlay were then removed
from the wells and the plaques were enumerated.
To determine the 50% tissue culture infectious dose (TCID50), monolayers of
Vero C1008 cells were grown in 96-well plates and 100 µL of serial 10-fold diluted
samples in MEM containing 2% FBS, were added to the wells. Cells were then incubated
for 5 d at 37°C, 5% CO2 and then scored for CPE.
Cell lines and in vitro infections
Baby hamster kidney cells (BHK-21) from the American Type Culture Collection
were propagated in MEM (Sigma) supplemented with 10% fetal calf serum, 2 mM lglutamine, 50 IU/mL penicillin and 50 µg/mL streptomycin (Life Technologies). Nipah
virus infections were performed in 48-well plates when cells reached 95–100%
confluency. Infections were performed by replacing medium with 250 µL of diluted virus
(multiplicity of infection (MOI) of 0.1 and 0.01) in MEM, 2% FBS. After 1 hr, the
inoculum was replaced with MEM supplemented with 2% FBS. Supernatants were
collected at 1 hr, and 1, 2, and 3 days post infection (dpi) for virus titration. Cells were
stained using the Kwik Diff Kit (Thermo scientific) to visualize syncytia according to the
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instructions of the manufacturer. Cells were monitored for CPE with a light microscope
and images were captured using a Nikon DS-Fi1 camera.
Inoculation of hamsters and sample collection
Groups of 5 to 6 week old female Syrian hamsters (Harlan) were inoculated with
the indicated doses of NiV-M or NiV-B diluted in sterile DMEM and administered via
the i.p. route in a total volume of 500 µL. Control animals received the equivalent
volume of sterile DMEM by the same route. Two groups were inoculated i.n. with 105
TCID50 per hamster of either NiV-M or NiV-B diluted in sterile DMEM. Fifty
microliters of virus preparation was delivered to each nare using a pipette. Hamsters were
weighed and scored daily for clinical signs for two weeks. When signs of disease no
longer existed, animals were monitored but no longer weighed. The health of animals
was assessed and scored according to the following criteria: 0 = no signs of disease; 1 =
ruffled fur; 2 = ruffled fur & weight loss <5%; 3 = ruffled fur, hunched posture & weight
loss >5%; 4 = ruffled fur, hunched posture & weight loss >10%; 5 = ruffled fur, hunched
posture, weight loss >15%, or encephalitic signs, or hemorrhagic signs, or paralytic signs
or dyspnea; 6 = ruffled fur, hunched posture, weight loss >20%, or encephalitic signs, or
hemorrhagic signs, or paralytic signs or dyspnea; 7 = death. Euthanasia occurred at a
score of 5 and above. At the time of euthanasia, animals were bled (EDTA- and heparintreated vacutainer tubes) via cardiac puncture. Necropsies were performed to collect lung,
spleen, heart and brain tissue. Tissues were placed in lysis buffer RLT (Qiagen) for RNA
extraction, or 10% formalin for histopathology and immunohistochemistry (IHC)
analysis.
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RNA extraction and quantitative real-time RT-PCR (qRT-PCR)
Tissues (30 mg pieces) were homogenized in RLT buffer and removed from the
BSL4 using approved standard operating procedures. Total RNA was extracted using
RNeasy kit (Qiagen), according to the manufacturers' instructions. Whole blood was
collected and inactivated in AVL buffer and removed from the BSL4 using approved
standard operating procedures. Total RNA was extracted using QIAamp viral RNA kit
(Qiagen), according to the manufacturers' instructions.
The RNA was quantified on a nanodrop 8000 spectrophotometer (Thermo
Scientific). Real-time quantitative RT-PCR (qRT-PCR) was performed on a rotor-gene
6000 instrument (Corbett Life Science) using QuantiFast probe reagents (Qiagen)
targeting the NiV-M or NiV-B nucleocapsid protein gene. Primers and probes used were:
NiV-B sense (5′-GTTCAGGCCAGAGAAGCTAAATTT-3′), NiV-B antisense (5′CCTCTTCGTCGACATCTTGATCA-3′), NiV-M sense (5′GTTCAGGCTAGAGAGGCAAAATTT-3′), NiV-M antisense (5′CCCCTTCATCGATATCTTGATCA-3″), NiV-B probe (5′-6FAMCTGCAGGAGGTGTGCTCATCGGAGG-TAMRA-3′) and NiV-M probe (5′-6FAMCTGCAGGAGGTGTGCTCATTGGAGG-TAMRA-3″). qRT-PCR components were
used at the concentrations recommended by the manufacturer and 5 µL of RNA was
added to each reaction and the following thermocycling parameters were used: 50°C for
10 min, 95°C for 5 min, and 40 cycles of 95°C for 5 s, 60°C for 10 s. Dilutions of RNA
extracted from a known titer of each Nipah virus were run in triplicate to generate a
standard curve from which sample TCID50 equivalents were extrapolated. Hamster
immune gene expression was determined as previously described (126). Briefly, RNA
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was extracted from tissues and qRT-PCR was performed as described above using genespecific primers and probes under multiplex conditions. The fold-change in each gene
was calculated by normalizing the change in CT (ΔCT) to the CT values for RPL18 (as an
internal reference gene) for each sample and comparing this to the CT values of
uninfected hamsters (2−ΔΔCT).
Histopathology and immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin for 7 d with one volume
change, then transferred out of the BSL4 using approved standard operating procedures.
Tissues were then placed in cassettes and processed with a Sakura VIP-5 Tissue Tek, on a
12 hr automated schedule, using a graded series of ethanol, xylene, and ParaPlast Extra.
Embedded tissues were sectioned at 5 µm and dried overnight at 42°C prior to staining
with hematoxylin and eosin (H&E).
Specific Nipah virus IHC was performed using an anti-Nipah virus N protein
rabbit primary antibody at a 1:5000 dilution (kindly provided by L. Wang, CSIRO
Livestock Industries, Australian Animal Health Laboratory, Australia) (54). The tissues
were then processed using the Discovery XT automated processor (Ventana Medical
Systems) with a DAPMap (Ventana Medical Systems) kit.
Statistics
Statistical analyses were performed on the data form the TCID50 and qRT-PCR
experiments using a 2-way ANOVA with a Bonferroni's post-test. To determine whether
there were significant differences in the time to death between the viruses, we performed
a log-rank test. The mean and SEM is represented and significance (* = p<0.05, ** =
p<0.01 and *** = p<0.001) is reported where appropriate.
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Results
NiV-M causes increased cytopathology in BHK-21 cells, compared to NiV-B
To determine the cellular responses and replication kinetics of the two Nipah virus strains
in a hamster cell line, we infected BHK-21 cells with either NiV-M or NiV-B at MOIs of
either 0.01 or 0.1. As early as 1 dpi, syncytia formation was apparent in all NiV-Minfected cultures. By 3 dpi, and at both MOIs, NiV-M-infected cells showed extensive
CPE and nearly complete destruction of the cell monolayer (Figure	
  3-‐1A). NiV-Binfected cells showed little CPE at any of the time points sampled, regardless of the
inoculation dose. At 3 dpi, NiV-B-infected cells began to form small syncytia. At both
MOIs, NiV-M replicated sooner and reached higher virus titers in the supernatant at
earlier time points compared to NiV-B (Figure	
  3-‐1B and C). At the lower MOI, NiV-M
reached a titer that was 4 logs higher at 3 dpi than NiV-B (Figure	
  3-‐1B), whereas end
titers were similar for both Nipah virus strains at the higher MOI, with a faster
progression for NiV-M (Figure	
  3-‐1C).
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Figure	
  3-‐1:	
  NiV-M replicates more efficiently and causes increased
cytopathogenicity in hamster cells compared to NiV-B. 	
  
To study the cytopathogenicity of these Nipah viruses, BHK-21 cells were infected with
NiV-M or NiV-B at an MOI of 0.01 and stained using the Kwik Diff Kit at 1, 2, and 3
dpi. Arrows point to multinucleated giant cells (A). To examine the viral growth kinetics,
BHK-21 cells were infected with Nipah virus at an MOI of 0.01 (B) or 0.1 (C) and
supernatants were collected at the indicated time points. Supernatants of NiV-M at an
MOI of 0.1 at 3 dpi were not collected due to extensive destruction of the cell monolayer.
Virus was titrated on Vero C1008 cells and the results are expressed as the mean of three
replicates and error bars indicate the SEM. The dotted line denotes limit of detection for
the assay. A 2-way ANOVA with Bonferroni's post test was used to compare the viruses
(* = p<0.05) (B and C).
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Disease progression during NiV-B infection of hamsters is delayed compared to NiV-M
infection
To date, NiV-B infection has not been examined in an animal model. To assess the
suitability of the hamster as a model for NiV-B infection, as well as to compare the two
strains, hamsters were inoculated i.p. with 10-fold serial dilutions of Nipah virus from 105
to 1 TCID50 (Figure	
  3-‐2). Animals were evaluated for clinical signs of disease on a daily
bases according to a scoring system outlined in the Materials and Methods section. Only
one hamster showed abnormal clinical signs on the day prior to euthanasia, which
consisted of ruffled fur. All other hamsters did not display abnormal clinical signs until
the day euthanasia was necessary. Hamsters challenged with either virus strain showed
clinical signs of respiratory distress and/or neurologic dysfunction leading to a score that
required euthanasia. Signs of respiratory disease included labored abdominal breathing
and hunched posture; neurological dysfunction included imbalance, partial paralysis and
seizures. Similar to previous studies with NiV-M, respiratory distress was observed only
in animals infected at the highest doses (104 and 105 TCID50/animal) (53). The majority
of animals inoculated with the lower doses of Nipah virus (100 through 103
TCID50/animal) displayed neurologic dysfunction prior to euthanasia. One animal
infected with NiV-M at the highest dose (105 TCID50) and two animals infected with
NiV-B (one inoculated with 104 and one with 105) presented with both respiratory and
neurologic dysfunction, while the rest of animals had either respiratory or neurological
signs of distress that required euthanasia. NiV-M-infected animals showing severe
respiratory signs of disease were euthanized between 5–7 dpi, whereas animals
displaying neurological disorders were euthanized between days 5–11. Disease
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progression in NiV-B-infected animals was generally slower, and animals displaying
severe respiratory distress or neurological dysfunction were euthanized on 8–9 dpi or 8–
14 dpi for NiV-M and NiV-B infection, respectively (Table	
  3-‐1). The slower disease
progression in NiV-B-infected animals was reflected in the overall survival curves with
80% lethal disease outcome even at the highest dose of infection Figure	
  3-‐2:Hamsters
inoculated with NiV-B show delayed disease progression compared to NiV-M-infected
hamsters.and Table	
  3-‐1. The LD50 for NiV-M and NiV-B was 68 and 528 TCID50,
respectively. At both 103 and 105 TCID50, there was a statistically significant difference
in the time to death between the two virus strains, with death occurring approximately
two days later for NiV-B infected animals at each dose (Table	
  3-‐1). To determine if the
delay in survival is associated with the route of infection, we inoculated hamsters i.n.
with 105 TCID50 of either NiV-M or NiV-B. The mean time to death was delayed by two
days in hamsters inoculated with NiV-B compared to NiV-M (Figure	
  3-‐2). Both routes
of inoculation showed a two-day delay in NiV-B compared to NiV-M, although the mean
time to death was later in both virus groups with the i.n. compared to i.p. route.
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Figure	
  3-‐2:Hamsters inoculated with NiV-B show delayed disease progression
compared to NiV-M-infected hamsters. 	
  
Groups of 5 hamsters were inoculated i.p. with 10-fold serial dilutions of virus from 105
to 1 TCID50. The hamsters were monitored for 30 dpi for survival.
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Table	
  3-‐1: Clinical signs and outcome of hamsters inoculated with NiV-M or NiVB.	
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Figure	
  S	
  1:	
  Hamsters inoculated intranasally with NiV-B show delayed disease
progression compared to NiV-M-inoculated hamsters.	
  	
  
Groups of 5 hamsters were inoculated i.n. with 105 TCID50. The hamsters were monitored
for survival. A log- rank test was used to compare survival curves (* = p<0.05). NiV-B
infected animals had a mean time to death of 11.6 days and NiV-M infected animals 9.4
days.
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Both Nipah viruses replicate in hamster lung, brain and spleen tissue
To compare the pathogenesis of NiV-M to NiV-B, groups of hamsters were inoculated
with 105 TCID50 of either Nipah virus and tissues were collected on 1, 3 and 5 dpi for
both virus groups, and 7 dpi for NiV-B. Based on the time to death at this dose from our
survival experiment, 7 dpi tissues were not collected for NiV-M-inoculated animals for
this pathology experiment. Viral RNA was detected using Nipah virus N-specific qRTPCR (Figure	
  3-‐3). In NiV-M-inoculated animals, replication was detected at an earlier
time point than NiV-B replication. As early as 1 dpi, viral RNA was detected in lungs,
brain and spleen tissue of some NiV-M-infected animals. NiV-B-infected animals had
detectable levels of viral RNA at 1 dpi in lung tissue of some hamsters, and in the spleen
by 3 dpi. Both strains showed an increase in viral RNA over time in the lungs, brain and
spleen, with the highest overall titers in the lungs at the last time point sampled. We
assessed viremia in hamsters inoculated with either virus by qRT-PCR. Levels of viral
RNA were barely detectable and viral RNA was undetectable in some animals at each
time point (data not shown).
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Figure	
  3-‐3: NiV-B replication is delayed in hamster organs compared to NiV-M
replication. 	
  
Hamsters were inoculated with 105 TCID50 of Nipah virus and 9 animals/group were
euthanized at 1, 3, 5, and 7 (for NiV-B only) dpi and tissues were collected. Total viral
RNA was extracted and Nipah virus N-specific viral RNA was quantified by qRT-PCR.
Gray bars represent NiV-B and white NiV-M. Bars represent the mean and error bars
represent the SEM.
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Host gene expression in lung, brain and spleen tissue of hamsters is differentially
regulated during Nipah virus infection
To examine the kinetics of the host immune response to Nipah virus infection, and
compare responses between NiV-M and NiV-B infections, the expression level of a
subset of cytokine and chemokine mRNAs were examined by qRT-PCR in the lungs,
brain and spleen (Figure	
  3-‐4). Throughout the infection, the largest overall response was
seen in the lungs. At 1 dpi, a statistical difference in the upregulation of interleukin-4 (IL4), interleukin-6 (IL-6), tumor necrosis factor (TNF), and interferon-γ (IFNγ) was
observed between NiV-M and NiV-B infections, with higher expression of these genes in
response to NiV-M. A similar result was measured at 3 dpi for IFNγ in the lungs (Figure	
  
3-‐4). At 3 dpi, IL-4, IL-6 and TNF were upregulated similarly in response to both virus
strains and remained upregulated throughout the course of infection. Upregulation of the
gene for myxovirus resistance protein-2 (Mx2) in the lungs was detected only at the last
time point for both virus strains. IFNγ-induced protein 10 (IP-10) mRNA increased
starting at 1 dpi and remained upregulated in the lungs throughout the course of infection,
peaking at 3 dpi in NiV-M-infected hamsters and 5 dpi in NiV-B-infected hamsters. IL-4,
IL-6 and TNF were also upregulated in brain (Figure	
  3-‐4). There was a significant
increase in Mx2 transcription in the spleens of NiV-M-infected hamsters at 3 dpi
compared to NiV-B. In the brain, IL-4, IL-6 and TNF were slightly upregulated over
control animals. IL-4, IL-6, TNF, and IFNγ mRNAs were downregulated in the spleen.
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Figure	
  3-‐4:	
  Host gene expression in lung, brain and spleen tissue of hamsters is
differentially regulated during infection with Nipah viruses. 	
  
Quantitative RT-PCR for IL-4, IP-10, IL-6, Mx2, TNF and IFNγ was performed on lung,
brain and spleen tissues from groups of 9 hamsters inoculated with 105 TCID50 of NiV-M
(white bars) or NiV-B (gray bars) at the indicated time points. Data are shown as the
fold-change of each gene over uninfected controls and normalized to an internal reference
gene (RPL18). Error bars represent the SEM. A 2-way ANOVA with Bonferroni's posttest was used to determine statistical significance between viruses (* = p<0.05, ** =
p<0.01 and *** = p<0.001).
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Histopathological changes occurred earlier in NiV-M-infected hamsters compared to
NiV-B-infected animals
To compare the pathology between the two strains, hamsters were inoculated with 105
TCID50 of NiV-B or NiV-M and tissues were examined histologically. Pathology was
observed for both infections and was composed of a mild to moderate multifocal,
subacute, bronchointerstitial pneumonia with vasculitis on 5 dpi for NiV-M and NiV-B
infection (Figure	
  3-‐5). By 7 dpi in NiV-B-infected animals, the pneumonia progressed to
marked, multifocal to coalescing, subacute bronchointerstitial pneumonia with vasculitis,
necrosis, edema, and fibrin deposits. The pneumonia in both groups, on day 5 dpi for
NiV-M infection and 7 dpi for NiV-B infection, was characterized by effacement of
terminal bronchioles and adjacent alveoli by small to moderate numbers of macrophages,
neutrophils, lymphocytes and plasma cells. Multifocal vasculitis was observed with
disruption of the arterial tunica media by small numbers of neutrophils and lymphocytes.
Syncytial endothelial cells were found in affected small to medium caliber vessels.
Hamsters from the final time points had moderate to marked lesions in the lungs and
demonstrated a loss of pulmonary architecture with replacement by cellular and
karyorrhectic debris with small to moderate amounts of hemorrhage, fibrin deposits and
edema. IHC revealed viral antigen in alveolar capillary endothelium, small and medium
caliber arteriolar endothelium, and in mononuclear inflammatory cells starting at 3 dpi
for NiV-M infection and 5 dpi for NiV-B infection (Figure	
  3-‐5B). The presence of viral
antigen was strongly associated with areas of inflammation. No pathological changes
were observed in the CNS of hamsters infected at the high dose used in the pathology
study.
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Figure	
  3-‐5: NiV-M infection results in accelerated pathology compared to NiV-B
infection in hamsters.
Nipah virus inoculated hamsters were euthanized at 3, 5 and 7 dpi (for NiV-B only) and
lung sections were stained with H&E (A) and for Nipah virus nucleocapsid protein (IHC)
(B) Images were taken at a magnification of 100× and 400× (insets). Asterisks denote
arteries with vasculitis as demonstrated by recruitment of inflammatory cells with
effacement of the tunica intima and tunica media. Open arrows denote areas of acute
hemorrhage and closed arrows indicate fibrin deposits.
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Discussion
Nipah virus is a zoonotic pathogen that causes encephalitis and pulmonary disease
with a high case fatality rate and is classified as a category C pathogen by the NIAID's
pathogen priority list (120). Two strains of Nipah virus, NiV-M and NiV-B, have been
isolated from geographically and temporally separated outbreaks (28). Human outbreaks
caused by these strains differ in disease progression and epidemiologically (121). The
Syrian hamster has been established as a disease model for NiV-M infection (50, 53), but
NiV-B infection studies have not been reported for any animal model. The goal of this
study was to compare the replication, pathogenesis, and immune response to infection
with NiV-M and NiV-B using in vitro and in vivo methods. BHK-21 cells infected with
NiV-M showed more severe damage and supported higher virus replication compared to
NiV-B-infected cells. Hamsters infected with NiV-B had a delay in disease progression
and increased survival rates compared to NiV-M infected animals.
In vitro, BHK-21 cells were permissive for infection by both NiV-M and NiV-B.
NiV-M replicated to higher titers in the supernatant at an earlier time point, and infection
resulted in widespread syncytia formation causing extensive CPE. Widespread CPE was
not observed in NiV-B-infected BHK-21 cells, although a few syncytia were present at
later time points. The differences observed in virus replication and syncytia formation
could be attributed to either higher viral replication causing more syncytia, or more
syncytia formation resulting to higher virus load. Differences in replication efficiency
including protein production, viral assembly and budding could explain the higher virus
production and large number of syncytia observed in NiV-M infected cultures.
Conversely, differences in fusion kinetics could account for disparate amounts of
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syncytia that then lead to variation in virus replication. The high amount of fusion and
syncytia formation in cells could result in the infection of cells that were not initially
infected at the low MOIs used in our experiments. This could lead to higher overall levels
of virus production. Previous studies using paramyxoviruses have demonstrated that viral
spread can occur by cell-cell fusion; the surface proteins of Nipah virus are present at the
cell junctions and have been shown to initiate fusion and spread of virus (127–129).
Slower fusion kinetics could lead to less and slower formation of syncytia observed in
NiV-B infected cells. The affinity of Nipah virus glycoprotein to its receptors, ephrin B2
and B3, as well as the ability of the glycoprotein to trigger the fusion protein could also
affect fusion rates. Further experiments need to be completed to examine the relationship
between replication and syncytia formation.
In our experiments, we chose i.p. as the route of inoculation due to the more
uniform disease progression and outcomes described in previous Nipah virus studies (50).
It is likely that i.p. inoculation would more readily allow for the detection of subtle
differences between strains that may not be detectable in a less uniform infection route,
such as i.n. When infected with NiV-M or NiV-B, hamsters developed clinical signs of
disease similar to human infection (30, 50, 74, 75). The onset of disease and death in
hamsters was rapid and occurred between 5–14 dpi, which corresponds to human cases,
where symptoms start to develop between 7–10 dpi (24, 84, 130). We observed earlier
replication of NiV-M than NiV-B in all organ types sampled, although, once NiV-B RNA
was detected, it reached similar values within two days. Earlier replication of NiV-M in
tissues corresponded with earlier pathologic changes and accelerated disease and death
compared to NiV-B infection. In humans, CNS pathology is documented, but in our
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comparative pathology experiment, we did not observe pathology in the CNS. This is
likely attributed to the high dose of inoculum for the pathology experiment (105 TCID50)
and route of inoculation (i.p.). However, we did observe pathology in the lungs consisting
of multifocal subacute bronchointerstitial pneumonia with vasculitis. The pneumonia was
characterized by inflammation in the terminal bronchioles and alveoli spaces, necrosis,
hemorrhage, fibrin deposits, edema and syncytia in endothelial cells. In human cases,
fibrinoid necrosis, vasculitis, pulmonary edema, alveoli hemorrhaging, and syncytia were
documented (24, 75, 84). It is probable that hamsters inoculated with this high dose (105
TCID50) succumbed to infection due to inflammation, edema, and widespread vasculitis
in the lungs that caused interstitial pneumonia. Even with low levels of viral antigen,
pathology was severe enough to cause a fatal outcome.
The typical dose that humans are infected with, as well as the route of infection is
not known. In hamsters, both virus strains caused respiratory distress and/or neurological
dysfunction in a dose-dependent manner. Based on previous data in hamsters, it is likely
that dose and route of infection might play a role in Nipah virus outcome in humans (53).
Disease progression could be altered by the transmission route, which could include
fomite (51, 71), oral ingestion (60, 131), and respiratory droplets (51, 58, 132). In this
study, inoculation of hamsters with NiV-B resulted in a delay in disease progression and
the LD50 was approximately a log higher compared to NiV-M. However these data are
contrary to what has been reported in humans, where NiV-B results in higher case fatality
rates compared to NiV-M. Since we did not observe a difference in disease that would
explain differences in the epidemiological data for the two Nipah virus strains, factors
other than the intrinsic pathogenicity likely contribute to the disparities in the
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documented epidemiological data. The suboptimal health care, lack of supportive care
and inconsistencies in reporting could account for higher documented case fatality rates
and differences in disease manifestations during NiV-B outbreaks (73).
Cytokine and chemokine mRNAs were quantitated in the hamsters over the
course of infection and several immune genes were upregulated in the lung, brain, and
spleen, although there was a slight downregulation of some genes in the spleen. NiV-M
induced an earlier and more robust immune response compared to NiV-B, which
eventually reached similar levels to hamsters infected with NiV-M. Early TNF activation
during NiV-M infection may contribute to recruitment of inflammatory cells, as observed
in the lungs of infected hamsters by histopathology. The upregulation of IP-10 in the
lungs coincided with lymphocyte recruitment, appearance of vascular damage, and
necrosis in the lungs. IP-10 upregulation has been documented in other Nipah virus
studies, specifically focusing on endothelial cells (133, 134). Teruya-Feldstein et al
reported that high levels of IP-10 are found in necrotic tissue and in areas of vascular
damage associated with Epstein-Barr virus-positive lymphoproliferative processes in
mice (135). They demonstrated a correlation between IP-10 regulation, tissue necrosis,
and vascular damage during viral infection. Similarly, IP-10 is upregulated in the airways
of patients with pulmonary diseases such as tuberculosis and plays a role in recruitment
of activated T cells (136). IL-6 gene expression was increased earlier in the lung in NiVM compared to NiV-B infected hamsters. IL-6 activates T cells (137) and the recruitment
of T cells likely contributed to the widespread vasculitis associated with Nipah virus
infection and disease. Recruitment of lymphocytes could also be a way for Nipah virus to
disseminate throughout the host, as it has recently been published that lymphocytes and
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monocytes can carry virus without becoming infected and release virus at distant sites
from the original infection (83, 138). In the lungs, IL-4 was also upregulated, following
similar kinetics than IL-6. IL-4 promotes differentiation of B cells, and is upregulated is
indicative of the activation of a Th2 response (139). However, during disease, specific
antibody production would not occur fast enough, since animals succumb to infection
before significant antibody production can likely occur. Due to the use of the hamster as a
model, we are limited in the amount of reagents available for a detailed examination of
the immune response and future work is needed to get a more complete picture of the
immune response to Nipah virus infection. In general NiV-M infection caused earlier
induction of immune genes which probably corresponds to the earlier pathology
observed. It is possible that the strong early immune response in Nipah virus-infected
animals might contribute to disease via an immunopathogenic mechanism.
In conclusion, there is a delay in NiV-B-induced disease progression compared to
NiV-M, specifically in time to death, virus replication, pathology and immune responses.
NiV-M is more cytopathic in vitro and more pathogenic in vivo. Viral antigen staining
was low in tissues, although the pathologic changes were extensive and the inflammatory
response was robust, suggesting disease progression may not only be a result of direct
effects of the virus, but likely has an immunopathogenic component. The experimental
data presented herein characterizes the hamster as a suitable small animal model for NiVB infection, showing clinical signs, viral tropism, and pathologic changes similar to those
observed in humans. These data are important to further the understanding of Nipah virus
infection and pathogenesis. By applying the hamster model for NiV-B this allows for
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future studies in transmission, pathology and therapeutics, specifically focusing on the
Nipah virus strain responsible for recent outbreaks.
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CHAPTER 4 CHARACTERIZATION OF CELL-TYPE SPECIFIC INFECTION
OF NIPAH VIRUS IN VITRO AND IN VIVO
Abstract
Nipah virus infects humans and animals causing respiratory distress and
encephalitis. Infection with Nipah virus is systemic causing wide spread vasculitis.
Previous studies have identified vascular endothelial and smooth muscle cells as targets
of infection. In this study we provided further evidence for infection in vivo in these cells
as well as characterized pathology in endothelial cells and lack thereof in smooth muscle
cells. To further define effects of infection on these cells we used primary human cells in
vitro. Experiments in culture revealed that both cell types are permissive to infection and
can produce high virus titers. Similar to the situation in vivo in humans and animals there
was little change in smooth muscle cell morphology following infection. We discovered
that smooth muscle cells unlike endothelial cells do not express measureable amounts of
Nipah virus receptor on the surface, which prohibited fusion and viral spread. These data
suggest that smooth muscle cells get infected ephrin-independently and act as a
continuous source for virus production.
Introduction
Nipah virus is a zoonotic pathogen causing respiratory distress as well as
encephalitis in humans. It is a member of the genus Henipavirus in the family
Paramyxoviridae. Since its discovery in 1998 in Malaysia and Singapore, Nipah virus has
been found to be the cause of almost yearly outbreaks on the Indian subcontinent. The
natural reservoir of the virus is the pteropid fruit bat (32). During the Malaysian outbreak
the pig was identified as an intermediate host amplifying and spreading the virus to
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humans (118). In Bangladesh, where current outbreaks occur, Nipah virus is transmitted
from bats to humans and then from human to human (72).
Clinical infection in humans is characterized by fever, cough, dyspnea, headache
and loss of consciousness. Average duration of illness is 9 days, resulting in mortality in
about 70% of patients (75). Autopsies of patients have found common hallmarks of
Nipah virus disease including systemic vasculitis, endothelial destruction, and CNS
involvement (76, 80). More specifically, Nipah virus causes vasculitis of small blood
vessels of the CNS, lung, heart, and kidney. The endothelium of medium to large vessels
seems to be refractory for Nipah virus infection (62). Vessels infected with Nipah virus
show inflammation with leukocyte infiltration, thrombosis, necrosis, as well as
hemorrhages (80). Vasculitis of these vessels is often described as destruction of the
endothelium with fibrinoid necrosis. Part of the destruction of the endothelium is the
formation of giant multinucleated cells, called syncytia.
The two main target organs of Nipah virus infection are brain and lung. Infection
of the CNS produces viral inclusions throughout the white and gray matter resulting in
degeneration and perivascular cuffing (75, 77, 80). Immunohistochemistry (IHC) of the
brain for Nipah virus antigen results in positive staining of blood vessels and neurons that
are associated with vasculitis and necrotic plaques (56, 77). Pathologic changes in the
lung are also characterized by vasculitis and necrosis in small blood vessels. Syncytia can
been found in alveolar spaces causing pulmonary edema. Viral antigen staining is seen in
the endothelium and tunica media of blood vessels as well as in the alveolar spaces of the
lung (140).
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Pathologic findings correspond to Nipah virus receptor expression. The receptors
for Nipah virus has been identified as the receptor tyrosine kinase ephrin B2 and B3 (7, 8,
12). The receptor is a highly conserved transmembrane ligand that normally functions in
cell-to-cell signaling, angiogenesis and neuronal axon guidance (9, 11). The highly
conserved receptor is thought to account for the broad species tropism of Nipah virus
(82). Expression of ephrin B2 is localized to arterial endothelial cells, smooth muscle
cells and neurons with high expression in the lung and brain, while ephrin B3 expression
is restricted to the brain stem and heart (7, 8, 10, 12, 17). The expression levels of ephrins
are regulated in organs and during various times in the cell cycle, thus limiting Nipah
virus infection to organs with high expression (10).
In cell culture, various cell lines have been evaluated for permissibility to Nipah
virus infection as well as ephrin expression. In most cases infection has been directly
linked to ephrin expression; however a few cases of ephrin-independent infection have
been reported including the possibility of macropinocytosis (13, 82, 83).
The goal of this study was to characterize virus replication and cytotoxicity in
both endothelial cells and smooth muscle cells during Nipah virus infection. We first
detected Nipah virus infection in the endothelium and tunica media in vivo in tissue
derived from infected hamsters and African green monkeys. Subsequently, we found that
both primary cultures of human endothelial and smooth muscle cells are permissive to
infection resulting in cytotoxicity in endothelial but not smooth muscle cells. The noncytotoxic phenotype was associated with the low to no ephrin expression decreasing viral
cell-to-cell spread and syncytia formation. Overall our results suggest that Nipah virus
can infect smooth muscle cells by an ephrin-independent manner and serve as a source
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for virus propagation without cell destruction. We also demonstrate that primary human
endothelial and smooth muscle cells are a suitable in vitro system mirroring vascular in
vivo infection.
Materials and Methods
Ethical statement
All work with Nipah virus and potentially infectious materials and animals was
completed in the BSL4 facility at the Rocky Mountain Laboratories, Division of
Intramural Research, National Institute of Allergy and Infectious Diseases, National
Institutes of Health. The Institutional Biosafety Committee (IBC) approved all standard
operating procedures applied. Animal experiments were approved by the Institutional
Animal Care and Use Committee of the Rocky Mountain Laboratories and performed
following the guidelines of the Association for Assessment and Accreditation of
Laboratory Animal Care, International (AAALAC) by certified staff in an AAALACapproved facility.
Cells and Virus
Vero C1008 cells (European Collection of Cell Cultures, Salisbury, UK), primary
human microvascular lung endothelial cells (EC) (Lonza), and primary human pulmonary
artery smooth muscle cells (SMC) (Lonza) were purchased and propagated according to
manufactures reconditions. HeLa cells expressing ephrin B2 or ephrin B3 were kindly
provided by Chris Broder (Uniform Services University, MD). Nipah virus (Malaysian
strain) was kindly provided by the Special Pathogens Branch of the Center for Disease
Control and Prevention, Atlanta, GA, USA. Virus were propagated on Vero E6 cells in
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Dulbecco's Modified Eagle’s medium (DMEM) (Sigma) supplemented with 10% fetal
calf serum, 2 mM l-glutamine, 50 IU/mL penicillin and 50 µg/mL streptomycin (Life
Technologies) and supernatants were clarified by low-speed centrifugation and stored in
liquid nitrogen.
Tissue staining
Historical tissue blocks from Nipah virus infected hamster (140) and African
green monkey (AGM) (104) were analyzed for effects of infection on endothelial and
smooth muscle cells. Embedded tissues were stained with hematoxylin and eosin (H&E).
Specific Nipah virus IHC was performed using an anti-Nipah virus nucleocapsid rabbit
primary antibody at a 1:5000 dilution (kindly provided by L. Wang, CSIRO Livestock
Industries, Australian Animal Health Laboratory, Australia) (54). The tissues were then
processed using the Discovery XT automated processor (Ventana Medical Systems) with
a DAPMap (Ventana Medical Systems) kit. Tissues were also stained for with 1:100 antismooth muscle actin mouse monoclonal (Millipore) and 1:700 anti-CD31 (LifeSpan
BioSciences) for identification of smooth muscle cells and endothelial respectively.
In vitro infection
Nipah virus infection was performed on cells in 48-well plates when cells had
reach 90-95% confluence. Growth media was removed and diluted virus was added in
250 µL of fresh media (multiplicity of infection (MOI) of 5, 0.1, and 0.01). After 1 hr, the
inoculum was replaced with fresh media. Supernatants were collected at 1 hr, and for
every day after infection up to 20 days for virus titration. On a separate plate, cells were
infected as above and stained using the Kwik Diff Kit (Thermo scientific) to visualize
syncytia according to the instructions of the manufacturer. Cells were monitored for
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cytopathic effect (CPE) with a light microscope and images were captured using a Nikon
DS-Fi1 camera. Cells were grown on 8-well chamber slides and infected as above at an
MOI of 5. These cells were fixed at the designated time points in formalin for 24 hours
then the formalin was replaced and the samples were removed from BSL-4 for
immunofluorescence.
Virus visualization
Vero C1008 cells were grown to confluence in 96-well plates in normal growth
media. Ten-fold serial diluted samples in Dulbecco's Modified Eagle’s medium (DMEM)
(Sigma) supplemented with 2% fetal calf serum, 2 mM l-glutamine, 50 IU/mL penicillin
and 50 µg/mL streptomycin (Life Technologies) were added to the well. Cells were then
incubated for 5 days at 37°C, 5% CO2 and the scored for CPE.
For viral protein expression, SMC were infected with Nipah virus at MOI 1, and
0.01 and cells were collected in SDS buffer 2 days later. Cells were centrifuged and the
cell pellet was used for 10% SDS-polyacrylamide gel electrophoresis. Proteins were
transferred to a PVDF membrane (GE healthcare, UK) and probed with Nipah N specific
rabbit sera (kindly provided by L. Wang, CSIRO Livestock Industries, Geelong,
Australia).
Chamber slides, for immunofluorescence, were infected with Nipah virus at an
MOI of 5 then fixed at the designated time point in 10% formalin overnight. Formalin
was then exchanged and slides were taken out of BSL4. After fixation, slides were
washed in PBS then incubated in 0.2% triton x100 for 7 minutes followed by blocking in
PBS/4% BSA for 10 minutes. Slides were then incubated in Nipah N specific rabbit sera
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followed by anti-rabbit alexa 488. ProLong Gold antifade reagent with DAPI (Invitrogen)
was applied to the slides and all slides were visualized by confocal microscopy.
Ephrin expression
Endogenous expression of ephrin was quantified in cell culture by flow
cytometry. Cells were collected for flow cytometry and washed using PBS containing 15
mM EDTA. Cells were incubated with recombinant Human EphB4 (the ligand to Nipah
virus receptor ephrin B2/ B3) labeled with human FC (R&D) for 1 hr, washed then
incubated with anti-human IgG (H+L) alexa 647 (Life Technologies) and fixed in 4%
paraformaldehyde (PFA). Flow cytometry was performed using an LSR II (BD
Biosciences) and data were analyzed using FlowJo software (Treestar Inc.).
Lentivirus infection and co-cultures
SMC and EC were transduced with lenti viruses expressing red fluorescent
protein (RFP) or green fluorescent protein (GFP) (Cellomics Technology) respectively
per the manufactures protocol. Briefly, cells were incubated in growth media with 6 µg
polybrene, and lentivirus stock for 24 hrs at 37°C followed by regular growth media
exchange. Fluorescing SMC and EC cells were mixed in culture before Nipah virus
infection (MOI 5). Cells were visualized for syncytia formation, CPE, and virus infection
by Kwik Diff Kit and IFA.
Ephrin transfections and infections
SMC were transfected with human ephrin B2 in a CMV promotor driven
expression plasmid (Sino Biological Inc.) or Nipah virus fusion (F) and glycoprotein (G)
using the Nucleofector kit for primary smooth muscle cells (Lonza). Cultured cells at
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5x105 in Nucleofector solution were mixed with DNA (1 µg ephrin, and 1 µg of F and 1
µg G) then loaded into a cuvette. The Nucleofector device was used with program A033
after which media was added to cells and cells were plated in 12-well plates. In the case
of F and G transfection, cells were mixed with EC the day after transfection and then
stained with Kwik Diff Kit 24 hrs later. After 2 days, ephrin B2 transfected cells, were
transferred into BSL-4 and infected at MOI 5 with Nipah virus. Cells were observed for 2
days and stained by Kwik Diff Kit.
Results
Nipah virus infects smooth muscle and endothelial cells of the lung vasculature with
distinct cytopathogenicity
Nipah virus infection in hamsters and African green monkeys (AGM) is
characterized by systemic infection with vasculitis. In order to better understand the
cellular targets of Nipah virus infection we focused on the vasculature of the lung, one of
the target organs of infection. Historic tissue blocks of hamsters and AFMs lungs were
used to identify vascular cells infected with Nipah virus. The hamster tissue was derived
from animals 5 days after intraperitoneal infection with 1000 LD50 of Nipah virus and
AGM tissues was derived from animals 10 days after intratracheal infection with 1x105
PFU of Nipah virus. Tissues were stained for Nipah virus nucleocapsid as well as
endothelial marker CD31 and smooth muscle actin to visualize infection in the vascular
endothelial and tunica media. Stained sections showed Nipah virus positive cells
surrounding small arteries in both hamsters and AGMs (Figure	
  4-‐1). Closer inspection
showed antigen positive cells within the actin smooth muscle layer and the endothelium.
Pathology observed in the tissues originated in the endothelial layer with syncytia
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formation only observed in the endothelium of infected animals. Pathology was absent in
the tunica media (Figure	
  4-‐1). These data are similar to what has been reported from
human infections.
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Figure	
  4-‐1:	
  In	
  vivo	
  lung	
  sections	
  confirm	
  Nipah	
  virus	
  antigen	
  in	
  endothelial	
  
and	
  smooth	
  muscle	
  cells.	
  	
  
Lung tissue from hamsters (left column) and African green monkeys (right column) were
sectioned and stained. The top row is stained with H&E. Asterisks denote vascular
degeneration of EC, stars denote hemorrhage and arrowheads denote perivascular
inflammation. The middle row shows staining for anti-smooth muscle actin in green and
virus necleocapsid in red. Arrows point to infected SMC and arrowheads to infected EC.
The last row is tissue stained for anti-CD31 in brown and viral nucleocapsid in red.
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Primary human endothelial and smooth muscle cells support Nipah virus replication
	
  
To determine effects of Nipah virus infection on endothelial and smooth muscle cells in
vitro, we used primary human microvascular endothelial cells from the lung (EC) as well
as human pulmonary artery smooth muscle cells (SMC). We infected monolayers of both
cells with Nipah virus at an MOI of 5, 0.1, and 0.01 and collected supernatants starting 1
hour after infection and continuing until extensive cytopathic effect (CPE) was observed
(for EC) or primary cell viability decreased (for SMC). Cells were observed for CPE,
syncytia formation, or other morphologic changes throughout the experiment. As early as
1 day following infection EC cells started to undergo morphologic changes including
formation of syncytia (Figure	
  4-‐2A). By day 3, most EC cells were dead and peeled off
the plate, showing complete destruction of the monolayer by Nipah virus infection. In
contrast, SMC cells did not show any CPE or morphologic changes over 3 weeks in
culture (Figure	
  4-‐2A).
To assess the ability of Nipah virus to infect SMC, as seen in vivo, we collected cells 2
days after infection to test for Nipah protein expression (B). Western blot analysis using
an anti-Nipah N polyclonal serum confirmed infection and replication in SMC. Viral
growth kinetics from primary cells confirmed that both EC and SMC supported Nipah
virus replication (Figure	
  4-‐2). At both, high and low MOI, EC produced high viral loads,
reaching peak titers already by day 1 or 2; these cells showed complete CPE on day 3
post infection. In contrast, SMC showed lower viral titer at early time points after
infection compared to EC but reached similar high titer a few days later. Titers in SMC
remained relatively high over an extended period of time with no obvious CPE. These
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data demonstrate that both endothelial and smooth muscle cells can be infected in vitro
mimicking the distinct pathology seen in infected animal models and human cases.

	
  

75	
  

	
  
	
  

	
  

	
  

76	
  

	
  
Figure	
  4-‐2:	
  Human	
  primary	
  endothelial	
  and	
  smooth	
  muscle	
  cells	
  are	
  
permissive	
  to	
  Nipah	
  virus	
  infection.	
  	
  
(A) Morphologic effects of Nipah virus infection on cells. EC and SMC were infected at
an MOI of 0.1 and morphologic changes were visualized with the Kwik Diff Kit on days
1, 3, and 5 post infection. (B) Protein expression of Nipah virus nucleocapsid. SMC were
infected at MOI 1 and 0.01 or mock infected and collected for western blot analysis 2
days post infection. Nipah virus proteins were used as a positive control in lane 1. (C)
Quantification of viral replication in primary cells. Cells were infected at a MOI of 1 or
0.1 and supernatants were collected at the designated time points. Viral progeny in the
collected supernatant was measured by a TCID50 assay.
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Smooth muscle cells have limited cell-to-cell spread compared to endothelial cells
	
  
To further characterize cell susceptibility including identifying number of initially
infected cells and fusion capacity in cultures, we performed an immunoflourscent time
course study in EC and SMC. Cell monolayers were infected at an MOI of 5 for an hour,
washed and incubated until fixed at the designated times shown (Figure	
  4-‐3), then
stained with anti-Nipah N polyclonal serum. Expression of Nipah viral nucleoprotein was
first observed at 8 hours post infection (hpi) in EC and by 10 hpi in SMC. By 12 hpi EC
samples showed the first evidence of syncytia formation followed by large syncytia and
100% infection by 14 hpi and cell destruction over the next 2-4 hours (Figure	
  4-‐3). In
contrast to EC, SMC infection remained focal with little to no syncytia formation and a
lack of cell-to-cell virus spread (Figure	
  4-‐3). These data suggest differences in virus
entry, replication and/or maturation limiting Nipah virus infection to individual smooth
muscle cells in contrast to a fulminant infection throughout the EC monolayer.
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Figure	
  4-‐3:	
  Visualization	
  of	
  Nipah	
  virus	
  infection	
  over	
  time	
  in	
  endothelial	
  and	
  
smooth	
  cells.	
  	
  
EC and SMC cultures were infected at a MOI of 5 and samples were fixed in formalin at
the designated time point (8 hrs through 2.5 d post infection). Cells were permeabilized
with triton x100 then stained with an anti- Nipah virus nucleocapsid antibody (green) and
DAPI (blue).
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Primary smooth muscle cells have minimal ephrin B2/B3 surface expression

Since infection of SMC is very inefficient, even with a high MOI, and the virus
shows little ability to spread from cell-to-cell by initiating fusion, we hypothesized that
SMC might express little or no ephrin B2/3. In order to test this hypothesis we used flow
cytometry to measure ephrin expression on the cell surface. Cells were grown to
confluency and then incubated with recombinant human EphB4-FC (the receptor for
ephrin ligand). Analysis of both Vero and EC, which both are susceptible to cytolytic
replication of Nipah virus, expressed measurable amounts of ephrin on their cell surface
(Figure	
  4-‐4). In contrast, SMC showed little to no measureable ephrin surface
expression. The lack of a functional receptor explains the low percentage of infected
SMC seen in vivo and in vitro.
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Figure	
  4-‐4:	
  Smooth	
  muscle	
  cells	
  show	
  little	
  ephrin	
  expression	
  on	
  the	
  cell	
  
surface	
  compared	
  to	
  more	
  susceptible	
  cells.	
  	
  
Cells were collected and surface stained for ephrin expression by flow cytometry using
recombinant EphB4-FC. Tinted histograms represent negative controls and colored lines
represent replicates. HeLa cells were used as negative control cells and HeLa cells
stabling expressing either ephrin B2 or B3 were used as positive controls.
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Ephrin expression promotes spread of Nipah virus in smooth muscle cells

To test whether SMC are capable of fusing we transfected them with Nipah virus
fusion and glycoprotein and mixed them with EC, with the notion that the glycoproteins
on the SMC surface would fuse with the naïve EC expressing RFP. Alone, the transfected
SMC did not fuse, but in combination with EC, wide-spread syncytia were observed
(Figure	
  4-‐5A,B). The involvement of EC in the syncytium (Figure	
  4-‐5C) was confirmed
by the presence of RFP which was expressed only in EC (Figure	
  4-‐5D); which could
only fuse by binding SMC expressing Nipah virus glycoproteins.
To further confirm the fusogenic capacity of SMC and EC we co-cultured the
cells and then infected them with Nipah virus (Figure	
  4-‐5,F). For this experiment, cells
were fluorescently labeled using a lentivirus system, SMC-RFP and EC-GFP, in order to
distinguish the cell types. In the co-cultures, we observed some cases where fusion
occurred between SMC and EC (Figure	
  4-‐5F) resulting in a colocalization of flourscent
proteins (RFP and GFP) and with viral proteins (white) in the cytoplasm. Fusion was not
observed in uninfected mixed cultures (Figure	
  4-‐5E). These data show that SMC are
capable of fusing with cells that express ephrin on their surface.
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Figure	
  4-‐5:	
  Smooth	
  muscle	
  cells	
  expressing	
  Nipah	
  glycoproteins	
  are	
  able	
  to	
  
fuse	
  with	
  naïve	
  endothelial	
  cells	
  in	
  mixed	
  culture.	
  
(A) Glycoprotein transfection of SMC enables fusion with EC. SMC cultures were
transfected with Nipah virus fusion and glycoprotein using nucleofector then mixed with
naïve EC. Cells were visualized with Kwik Diff Kit and demonstrate syncytia formation
24 hrs after mixing. (B) Infected smooth muscle cells mixed with naïve labeled
endothelial cells results in labeled syncytia. EC were transduced with lenti-RFP prior to
being mixed with SMC. SMC were infected at an MOI of 5, incubated for an hour,
washed and mixed with EC expressing RFP. One day after –culturing syncytia were
observed. An example of a SMC is outlined in orange, EC in yellow, and a syncytium in
blue for better visualization. (C) Visualization of virus infection and syncytia in mixed
culture of smooth muscle and endothelial cells. SMC and EC were transduced with
lentivirus constructs expressing either GFP or RFP, respectively. After expression was
confirmed cells were mixed followed by infection with Nipah virus at an MOI 5 (right
panel) or mock infection (left panel). Cells were fixed 12 hrs after infection and stained
with anti-Nipah nucleocapsid antibody (white) and dapi (blue). Syncytia composed of
both SMC and EC are yellow in color.
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Ephrin expression in smooth muscle cells rescues characteristic Nipah virus cytopathic
effect and syncytia formation

To further confirm the role of ephrin for cytolytic Nipah virus replication in SMC,
we transfected SMC with a plasmid expressing either ephrin B2 or an irrelevant protein
(GFP) prior to infection. Plasmid transfection did not result in morphologic changes
(Figure	
  4-‐6). Two days post transfection SMC were infected with Nipah virus at an MOI
of 5 and observed for morphologic changes as an indicator for Nipah virus replication
and spread. As early as 24 hpi small-scale syncytia started to form in SMC (Figure	
  4-‐6).
At 48 hpi transfected cells were fused and started to show typical CPE. This experiment
demonstrates that Nipah virus cytotoxicity in SMC can be achieved through expression of
ephrin B2 on the cell surface.
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Figure	
  4-‐6:	
  Ephrin	
  expression	
  on	
  the	
  surface	
  of	
  smooth	
  muscle	
  cells	
  rescues	
  
Nipah	
  virus	
  induced	
  cytopathology	
  including	
  syncytia	
  formation.	
  	
  
SMC were either transfected with a GFP or ephrin B2 expression plasmid using
nucleofactor reagent. The left panel shows naïve, the middle GFP transfected and the
right 2 panels ephrin B2 transfected SMC. Cells are shown non-infected (top row) or
after 24 (middle row) and 48 hr (bottom row) post infection. Cells were visualized by
light microscopy at 24 hrs and then stained with Kwik Diff Kit at 48hrs post infection.
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Discussion
Nipah virus is a zoonotic pathogen that causes encephalitis and respiratory
distress in humans. Since its discovery in 1998 in Malaysia Nipah virus has been
responsible for multiple smaller outbreaks in Bangladesh and India (121). The basic
understanding of Nipah virus pathology in humans is solely derived from a few early
autopsies; most of what we know about pathology is from studying disease in animal
models. The most commonly used models for Nipah virus that recapitulate human
disease are the hamster and the African green monkey (50, 56). A hallmark finding of
pathology reports from infected humans and experimentally infected animals is the
presence of viral antigen in the vasculature (141). Specifically, both endothelial cells
lining the luminal side of the vessels as well as the tunica media surrounding the vessel
walls have been reported as sites of viral replication (17). However, little is known about
their role in virus spread and pathology. The goal of this study was to better define the
role of endothelial cells and smooth muscle cells during Nipah virus infection.
In vivo we observed Nipah virus antigen systemically throughout the vasculature
of infected animals. Focusing on the lung, staining of hamster and AGM tissue identified
positive for viral antigen in the endothelium and the smooth muscle layers surrounding
vessels. We observed syncytia formation and pathology particularly in endothelial cells,
whereas smooth muscle cells seemed to be less infected with no obvious pathology.
Antigen staining of smooth muscle cells seemed to be localized to SMC of the tunica
media both in proximity to infected EC as well as in areas of uninfected EC. Indicating
that both EC and SMC can become infected independently of each other. Taken together
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our data confirms infection of endothelial and smooth muscle cells but raises the question
why there is different cytopathology.
To study possible explanations for differences in cytopathology between these
cell types we created an in vitro system using primary human cells. Human lung
endothelial cells (EC) and human smooth muscle cells (SMC) were selected as surrogates
for human vessels. Both primary cells were permissive to Nipah infection and replicated
virus to high titers. Interestingly, smooth muscle cells once infected did not undergo
morphologic changes, which mirror the situation in vivo. Unlike SMC, EC showed
widespread cytopathology including syncytia formation within hours of infection.
Interestingly it appeared that the SMC were persistently infected for the lifetime
of the primary cell culture, producing virus at high titer throughout. This phenomenon
could allow for continuous viral production with little host cell consequence, thus acting
as a virus production factory. Other viruses like rat virus (a parvovirus),
encaphlamyocarditis virus, cytomegalovirus and Epstein-Barr virus have the capacity to
infect SMC (142–146). Infection of SMC by Epstain-Barr virus and
encaphlamycardiditis virus leads to a lytic infection, proving that infection of SMC can
contribute to pathogensis of a viral infection (145, 146). In contrast, infection of SMC by
cytomegalovirus and rat virus leads to viral latency or persistence (142–144, 147). The
survival of infected SMC during viral infection in these systems leads to persistence
similar to our results for NiV infection. In vivo, viral replication in SMC appears to be
controlled by destruction of the surrounding EC, causing inflammatory cell recruitment
and necrosis of the surrounding tissue, eventually destroying the vascular architecture and
thus also affecting SMC.
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To further identify the mechanisms of Nipah infection of these cells we stained
infected cells over the lifetime of the primary culture for Nipah virus antigen. EC
exhibited 100% infection with mass syncytia formation in as short as 16 hpi. In contrast,
staining of SMC cultures revealed low level infection (about 10%) throughout with little
evidence of virus spread and no obvious cytopathogenicity. The differences in percentage
of infected cells between primary cells could account for the differences in CPE;
however, it does not account for the lack of syncytia formation. Previous studies
demonstrate that Nipah virus spread from cell-to-cell is accomplished by surface
expression of the Nipah glycoproteins of infected cells which than leads to fusion with
neighboring uninfected cells by interaction with the receptor, ephrin B2 or B3 (127, 148,
149). The non-fusigenic nature of these cells could be contributed to either ephrin
expression or an inability of the cells to fuse. Other explanations of viral spread include
viral production and spread from EC, from viral penetration through the damaged
endothelium, or through capillaries. Since we see SMC infected independent of EC
infection spread from EC or from damage to EC is unlikely.
Due to the low number of cells initially infected at a high MOI we choose to first
pursue receptor expression. Our experiment indicated that EC express ephrin on the cell
surface, while SMC showed little to no receptor surface expression. This supported our
hypothesis that there is a lack of receptor on the surface of SMC limiting viral infection,
spread and syncytia formation. How the original cells became infected in the absence of
the measurable surface receptor is yet unknown. Biologically smooth muscle cells
express ephrin during cell differentiation and maturing, and thus some cells in our
cultures could be of varying maturity (11, 150). This is, however, unlikely due to
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selection of cells for primary culture by using numerous mature smooth muscle markers.
It could also be that the amount of ephrin is lower than detection of our assay or that only
on a small percentage of cells in the population express it. Another explanation could be
that Nipah virus in SMC uses a different mechanism for viral entry. Early studies of
Nipah entry identified macropinocytosis as a possible entry mechanism for Nipah virus
(13). Another explanation could be the presence of a second receptor for Niaph virus
entry in SMC. For example, measles virus, a member of the same family, can use either
CD46 or SLAM as its cell entry receptor (151).
To further study the impacts of ephrin expression and the ability of SMC to fuse
we co-cultured either infected or glycoprotein transfected SMC with naïve EC. This
experiment resulted in fusion between SMC and EC demonstrating that SMC are capable
of expressing Nipah virus glycoproteins on the surface thus leading to fusion with EC.
We also transfected naïve SMC with human ephrin B2 followed by viral infection, which
resulted in productive Nipah virus replication and cytopathogenicity including syncytia
formation. Together these data demonstrate that the lack of host cell damage in smooth
muscle cells can be linked to the absence of receptor expression.
In this paper we investigated infection of EC and SMC by Nipah virus both in
vitro and in vivo. We found that both in tissue as well as cell culture smooth muscle cells
are productively infected; however, little SMC derived pathology is observed in either
case. We show that primary human SMC and EC can act as a surrogate system for Nipah
virus infection of the vasculature. By studying infection of this in vitro system, we
postulated that SMC could serve as a reservoir for Nipah virus production and or
persistence, much like infection with rat virus and cytomegalovirus. Previous research of
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SMC and EC interactions show that direct EC damage by virus infection can lead to
proliferation of SMC (152, 153). SMC express ephrin on their cell surface during
developmental stages and thus proliferation could account for differences in susceptible
of SMCs to Nipah virus infection . Even though previous papers have identified SMC as
a target of Nipah virus infection, this is the first study to specifically research the effects
of Nipah virus infection on SMC. Further research will have to identify potential
secondary receptors on target cells that lack ephrins such as SMC. A better understanding
of the mechanisms of Nipah virus infection will promote the development of new
therapeutic approaches against this serious regional public health threat.
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CHAPTER 5 SINGLE-DOSE LIVE-ATTENUATED NIPAH VIRUS VACCINES
CONFER COMPLETE PROTECTION BY ELICITING ANTIBODIES
DIRECTED AGAINST SURFACE GLYCOPROTEINS.
Abstract
Background: Nipah virus (NiV), a zoonotic pathogen causing severe repiratory illness
and encephalitis in humans, emerged in Malaysia in 1998 with subsquent outbreaks on an
almost annual basis since 2001 in parts of the Indian subcontinent. The high case fatality
rate, human-to-human transmission, wide-ranging reservoir distribution and lack of
licensed intervention options are making NiV a serious regional and potential global
public health problem. The objective of this study was to develop a fast-acting, singledose NiV vaccine that could be implemented in a ring vaccination approach during
outbreaks.
Methods: In this study we have designed new live-attenuated vaccine vectors based on
recombinant vesicular stomatitis viruses (rVSV) expressing NiV glycoproteins (G or F)
or nucleoprotein (N) and evaluated their protective efficacy in Syrian hamsters, an
established NiV animal disease model. We further characterized the humoral immune
response to vaccination in hamsters using ELISA and neutralization assays and
performed serum transfer studies.
Results: Vaccination of Syrian hamsters with a single dose of the rVSV vaccine vectors
resulted in strong humoral immune responses with neutralizing activities found only in
those animals vaccinated with rVSV expressing NiV G or F proteins. Vaccinated animals
with neutralizing antibody responses were completely protected from lethal NiV disease,
whereas animals vaccinated with rVSV expressing NiV N showed only partial protection.
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Protection of NiV G or F vaccinated animals was conferred by antibodies, most likely the
neutralizing fraction, as demonstrated by serum transfer studies. Protection of Nvaccinated hamsters was not antibody-dependent indicating a role of adaptive cellular
responses for protection.
Conclusions: The rVSV vectors expressing Nipah virus G or F are prime candidates for
new ‘emergency vaccines’ to be utilized for NiV outbreak management.
Introduction
Nipah virus (NiV; family Paramyxoviridae, genus Henipavirus) was discovered
to be the causative agent of an outbreak of viral encephalitis in pig farmers in Malaysia in
1998. This initial large outbreak has been followed by smaller nearly annual outbreaks in
Bangladesh and India (62, 74). Disease in humans is characterized by respiratory distress
and/or encephalitis, with histopathologic changes in the lung and brain showing
multinucleated giant cells throughout the microvasculature (62, 74, 80). NiV is highly
pathogenic in humans and has reached up to 100% case fatality rates (average 70%)
(154). Transmission of NiV from its natural reservoir, Pteropus fruit bats, to pigs and
humans has been documented, as well as human-to-human transmission (34, 44, 67).
Currently there are no approved vaccines or therapeutics for human use against
NiV infections. Although a public health concern to regional, national and even
international authorities, a widespread campaign to vaccinate a large percentage of the atrisk human population against NiV infection currently seems unfounded. Outbreaks are
rare, result in relatively few cases, are focal and isolated, and human-to-human
transmission is generally confined to health care workers and family members engaging
in close contact with exposed individuals, thus, rather favoring a ring vaccination
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approach. Therefore, a vaccine that produces a rapid and robust immune response after a
single immunization with the potential for peri-exposure application (‘emergency
vaccine’) would be most beneficial.
Current vaccine approaches for protection from NiV infection have focused on
the use of NiV glycoprotein (G) and/or fusion protein (F) as immunogens in various
platforms, including DNA vaccines, subunit vaccines, non-replicating vectors, as well as
replicating vectors (49, 54, 99, 105–113, 115, 116, 155, 156). Efficacy of most of the
previously tested vaccine candidates required a prime/boost(s) approach, which would
not favor their use in an emergency situation for rapid dissemination during an outbreak.
In order to develop a vaccine appropriate for ring vaccination, we generated liveattenuated recombinant vesicular stomatitis viruses (rVSVs) encoding individual NiV
proteins using the established reverse genetic system for VSV (157). The VSV system
has been used to generate vaccine candidates for many disease-causing viruses (158–
161). As a fast-acting single-dose vaccine, rVSV-based vaccines have been reported to
elicit effective humoral and cellular immune responses, as well as to protect periexposure (159, 162).
Herein, we tested the protective efficacy of three rVSVs expressing either the
nucleoprotein (N), F or G of the Malaysian strain of NiV. Following a single dose, the
vaccine vectors expressing G and F fully protected Syrian hamsters from lethal NiV
challenge, whereas the N expressing vector conferred only partial protection. Using
passive serum transfer, we further determined that full protection is conferred by
glycoprotein (F, G)-specific antibodies, most likely the neutralizing fraction, elicited by
the rVSV vaccines. However, other components of the immune system, such as cellular
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responses, also contribute to protection as demonstrated by partial efficacy and lack of
protection in passive transfer studies in the case of the N expressing vaccine vector.
Materials And Methods
Cells and Viruses.
Vero C1008 cells (European Collection of Cell Cultures, Salisbury, UK) and baby
hamster kidney cells expressing the bacteriophage T7 promoter (BHK-T7) (kindly
provided by Dr. Naoto Ito, Gifu University, Japan (163)) were used. NiV (Malaysian
strain) was kindly provided by the Special Pathogens Branch, Center for Disease Control
and Prevention, Atlanta, and propagated as previously described (140).
Generation of rVSV Vectors.
The plasmid pVSVXN2 (kindly provided by J. Rose, Yale University, New Haven) was
modified as previously described to encode the open reading frame (ORF) for Zaire
ebolavirus (ZEBOV) glycoprotein (GP) in place of that encoding the VSV glycoprotein
(G) (164, 165). NiV F, G, or N ORFs from the Malaysian strain of NiV, were amplified
similarly and cloned into pVSVXN2ΔG/ZEBOV-GP downstream of ZEBOV-GP
(Figure	
  5-‐1A). BHK-T7 cells were transfected using transit-LT1 Transfection Reagent
(Mirus, Madison, WI) along with individual plasmids encoding the VSV N, P, and L
ORFs and the modified VSV genomic plasmids as shown in Figure	
  5-‐1A. Cells were
incubated at 37°C for 7 days, at which time supernatant was collected and passaged once
on fresh Vero cells. Cultures were monitored daily for cytopathogenic effect (CPE) and
supernatants or cells were collected for sequence confirmation and analysis of protein
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expression. The rescued viruses are referred to as rVSV-ZEBOV-GP-NiVF, rVSVZEBOV-GP-NiVG and rVSV-ZEBOV-GP-NiVN.
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Figure	
  5-‐1:	
  Construction and characterization of recombinant VSV	
  (rVSV)	
  vectors
expressing NiV glycoprotein	
  (G),	
  fusion protein	
  (F),	
  or nucleoprotein	
  (N).	
  	
  
(A) Schematic representation of the vaccine constructs. rVSV-ZEBOV-GP-NiV
constructs were engineered by cloning NiV protein open reading frames into the vector
directly downstream of the ZEBOV-GP, which replaced VSV-G. (B) Verification of
foreign protein expression. ZEBOV-GP expression was verified by western blot analysis
of rVSV vector-infected cell lysates using the anti-ZEBOV-GP antibody 43.3.7.
Expression of NiV proteins was verified by flow cytometry. Cells were infected with the
different NiV protein-expressing rVSV vaccines (colored lines) or uninfected (gray lines)
and surfaced stained with antibodies specific for the respective protein, anti-G 1187 and
anti-F 835. In the case of N expression (colored line), cells were fixed in 4%PFA, then
permeabilized using saponin, followed by intracellular N-specific antibody staining. (C)
Verification of fusogenic activity of F and G. Vero C1008 cells were infected with rVSVZEBOV-GP-NiVF, rVSV-ZEBOV-GP-NiVG, or co-infected with rVSV-ZEBOV-GPNiVF and rVSV-ZEBOV-GP-NiVG at an MOI of 0.1, incubated for 2 days and stained
with the Kwik Diff Kit. Medium (DMEM) alone was used as a negative control.
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Analysis of Protein Expression.
Vero cells were infected with the different rVSVs at a multiplicity of infection
(MOI) of 1. Two days later, cell culture supernatants were collected, centrifuged, and the
resulting pellet was subjected to 10% SDS-polyacrylamide gel electrophoresis. Proteins
were transferred to a PVDF membrane (GE healthcare, UK) and ZEBOV-GP was
detected using the monoclonal antibody 43.3.7 (kindly provided by A. Takada, Hokkaido
University, Sapporo, Japan). Flow cytometry was performed to detect NiV F, G and N
expression. Virus-infected Vero cells (12 h post infection) were collected and washed in
PBS containing 15 mM EDTA. For surface staining, cells were incubated with the
primary antibodies anti-G 1187 (148) and anti-F 835 (kindly provided by Hector AguilarCarreno, Washington State University, USA), followed by incubation with goat antirabbit antibodies conjugated to Alexa 488 (Life Technologies) and fixed in 4%
paraformaldehyde (PFA). For intracellular staining, cells were fixed in 4% PFA for 10
min, then washed and incubated in buffer containing 0.2% saponin (Sigma) for 10 min.
After permeabilization, cells were incubated with an anti-NiV N rabbit antiserum (54)
(kindly provided by L. Wang, CSIRO Livestock Industries, Geelong, Australia), followed
by the above mentioned goat anti-rabbit antibodies in the presence of saponin. Flow
cytometry was performed using an LSR II (BD Biosciences, San Jose, CA) and data were
analyzed using FlowJo software (Treestar Inc., Ashland, OR). To measure the fusogenic
activity of expressed NiV F and G, Vero cells were grown in 48-well plates and infected
with individual rVSVs or co-infected with rVSV-ZEBOV-GP-NiVF and rVSV-ZEBOVGP-NiVG for 1 h at a MOI of 0.1. After 2 days, cells were stained and fixed with the
Kwik Diff kit (Thermo Scientific).
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Immunization and Challenge of Syrian Hamsters.
Groups of 10, 4-5 week old, Syrian hamsters (Harlan, Indianapolis, IN) were
vaccinated intraperitoneally (i.p.) with 105 plaque forming units (PFU) of the specified
rVSV vectors, or mock-vaccinated with DMEM in a total volume of 500 µL. Two days
prior to NiV challenge (day 26 post vaccination), blood was collected by retro-orbital
bleeding for analysis of antibody responses. After 28 days, animals were challenged i.p.
with 1000 LD50 (6.8 x 104 TCID50) of NiV and monitored for clinical signs of disease.
Necropsies were performed on four animals from each group 5 days post challenge to
measure viral load, attempt virus isolation, and assess histopathology. Brain, lung, and
spleen tissues were collected and placed in RLT lysis buffer (Qiagen, Valencia, CA) for
RNA extraction, and in 10% formalin for histopathology and immunohistochemistry
(IHC) analysis. The remaining six animals were used to monitor survival for 42 days post
challenge.
Immune Response to Vaccination.
Antibody responses were measured by enzyme-linked immunosorbent assay
(ELISA) as described previously (51). Neutralizing titers were determined by a
neutralizing tissue culture infections dose 50% (NTCID50) assay.
Histopathology and Immunohistochemistry.
Hamsters tissues were collected and processed as described previously (140).
Embedded tissues were sectioned and stained with hematoxylin and eosin (H&E) or the
above mentioned anti-NiV N rabbit antiserum at a 1:5000 dilution for
immunohistochemistry (IHC) (54).
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Quantitative Real-Time RT-PCR (qRT-PCR) and Virus Titration.
Tissues were processed for qRT-PCR as described previously targeting the NiV N
(140). Defined dilutions of NiV RNA were used in triplicate to generate a standard curve
from which sample TCID50 equivalents were extrapolated. NiV isolation and titration was
performed as previously described (51). A similar method was used in a qRT-PCR assay
targeting VSV N with the Fwd primer: CGGAGGATTGACGACTAATGC, Rev primer:
CGAGCCATTCGACCACATC and probe: FAM- CGC CAC AAG GCA G-MGB.
Passive Transfer of Antibodies.
Groups of 18, 4-5 week old, hamsters were vaccinated i.p. with 105 PFU of the
specified rVSV vaccine vectors. After 28 days, animals were exsanguinated via cardiac
puncture, serum was inactivated by gamma-irradiation (5 Mrads) and measured for
antibody titers by ELISA and NTCID50 assay as described above. Positive sera were
pooled from each group. Groups of six naïve hamsters were given 1 mL of serum i.p. 1
day prior to, and 1 day post i.p. challenge with 1000 LD50 (6.8 x 104 TCID50) of NiV and
monitored for clinical signs for 42 days.
Ethics and Biosafety.
All work with NiV was completed in the BSL4 facility at the Rocky Mountain
Laboratories, NIAID, NIH under standard operating procedures approved by the
Institutional Biosafety Committee. All animal experiments were approved by the
Institutional Animal Care and Use Committee and performed following the guidelines of
the Association for Assessment and Accreditation of Laboratory Animal Care,
International (AAALAC) by certified staff in an AAALAC-approved facility.
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Results
Rescue of replication-competent rVSV vectors
To generate rVSVs expressing NiV proteins, the F, G, or N ORFs were amplified and
individually inserted into pVSVXN2ΔG/ZEBOV-GP downstream of the ZEBOV-GP
gene as previously described (165) (Figure	
  5-‐1A). Individual genome constructs were
transfected together with the VSV helper plasmids into BHK-T7 cells and the
supernatants were passaged once onto fresh Vero cells. Cultures demonstrating CPE were
verified for viral protein expression using western blotting of whole cell lysates for the
detection of ZEBOV-GP, and flow cytometry for the detection of NiV F and G on the
cell surface and NiV N intracellular. All three rescued rVSVs expressed ZEBOV-GP, and
the individual viruses also expressed either NiV F, G, or N (Figure	
  5-‐1B). To verify the
structural and functional integrity of surface expressed NiV F and G, their fusogenic
activity was tested by co-infecting a monolayer of Vero cells with rVSV-ZEBOV-GPNiVF and rVSV-ZEBOV-GP-NiVG. We observed large-scale cell-to-cell fusion
resulting in multinucleated syncytia formation, a phenomenon that requires the presence
of functional NiV F and G on the cell surface (Figure	
  5-‐1C).
Immunization with rVSV vectors elicits strong specific antibody responses
The humoral immune response to vaccination was assessed in Syrian hamsters, a wellestablished NiV animal disease model (50, 53). Groups of 10 hamsters were immunized
with a single i.p. dose of 105 PFU of the different rVSV vectors (rVSV-ZEBOV-GPNiVF, rVSV-ZEBOV-GP-NiVG or rVSV-ZEBOV-GP-NiVN) and rVSV-ZEBOV-GP as
the control. After 26 days, blood samples were obtained and tested for NiV-specific
antibodies by ELISA using antigen prepared from whole inactivated NiV particles. In
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contrast to the animals in the control group (rVSV-ZEBOV-GP), all other vaccinated
animals showed high levels of antibodies titers ranging from 1600 to ≥3200 (Table 1). In
addition, we tested all sera for the presence of neutralizing antibodies against NiV. As
expected, vaccination of hamsters with rVSV-ZEBOV-GP or rVSV-ZEBOV-GP-NiVN
did not result in the generation of neutralizing antibodies (Table 1). In contrast, all
animals from the groups vaccinated with rVSV-ZEBOV-GP-NiVF and rVSV-ZEBOVGP-NiVG generated neutralizing antibody titers ranging from 80 to ≥640 (Table	
  5-‐1).
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Table	
  5-‐1:	
  Humoral	
  immune	
  responses	
  to	
  foreign	
  proteins	
  26	
  days	
  after	
  rVSV	
  
vaccination	
  as	
  measured	
  by	
  ELISA	
  (whole	
  inactivated	
  NiV	
  particle	
  antigen)	
  
and	
  NTCID50	
  assay	
  (against	
  live	
  Nipah	
  virus).	
  
	
  
ZEBOV-GP
Animal

	
  

NiV F

NiV G

NiV N

ELISA

Neut.

ELISA

Neut.

ELISA

Neut.

ELISA

Neut.

Titer

Titer

Titer

Titer

Titer

Titer

Titer

Titer

1

<20

<20

≥3200

160

≥3200

640

1600

<20

2

<20

<20

≥3200

80

≥3200

320

≥3200

<20

3

<20

<20

≥3200

160

≥3200

≥640

≥3200

<20

4

<20

<20

≥3200

80

≥3200

≥640

≥3200

<20

5

<20

<20

≥3200

320

≥3200

≥640

≥3200

<20

6

<20

<20

≥3200

180

≥3200

320

≥3200

<20

7

<20

<20

≥3200

320

≥3200

≥640

1600

<20

8

<20

<20

≥3200

320

≥3200

≥640

≥3200

<20

9

<20

<20

≥3200

320

≥3200

320

1600

<20

10

<20

<20

≥3200

320

≥3200

≥640

1600

<20
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Vaccination confers protection against lethal Nipah virus infection
The animals (10 per group) from the immune response study above were
subsequently challenged i.p. with 1000 LD50 of NiV. For the protection study we added a
group of six hamsters that was mock-vaccinated (DMEM). Six animals in each group
were monitored for survival. Animals in both control groups, DMEM and rVSVZEBOV-GP, developed clinical signs of disease between days 5 and10 post challenge,
resulting in respiratory distress with varying degree of neurologic dysfunction, and were
euthanized according to the approved protocol (Figure	
  5-‐2A). All animals in the groups
vaccinated with rVSV-ZEBOV-GP-NiVF and rVSV-ZEBOV-GP-NiVG were completely
protected from clinical disease with no significant weight loss (Figure	
  5-‐2A and B).
Hamsters vaccinated with rVSV-ZEBOV-GP-NiVN were partially protected (two of six
animals) with no clinical signs of disease, while the remaining four animals had to be
euthanized 9 days post challenge (Figure	
  5-‐2A, and B).
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Figure	
  5-‐2:	
  Survival of vaccinated hamsters following Nipah virus challenge.	
  	
  
Groups of six hamsters were vaccinated i.p. with 105 PFU of rVSV-ZEBOV-GP, rVSVZEBOV-GP-NiVF, rVSV-ZEBOV-GP-NiVG, rVSV-ZEBOV-GP-NiVN or mock
vaccinated (DMEM) 28 days prior to challenge with 1000 LD50 of NiV. (A) The
percentage of animals surviving over time. (B) Body weight loss over time. Weights are
shown as percentage of starting body weight.
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Vaccinated animals showed reduced viral loads and less pathology
In order to determine the impact of vaccination on virus replication, we collected
brain, lung and spleen tissues 5 days post NiV challenge from four hamsters of each
group described above for NiV load determination and isolation. Viral loads were
determined using a NiV N-specific qRT-PCR assay (Figure	
  5-‐3). All NiV-vaccinated
animals had lower organ levels of viral RNA compared to the animals in the control
groups (>103 TCID50 equivalent/mg tissue), with rVSV-ZEBOV-GP-NiVF and rVSVZEBOV-GP-NiVG vaccinated animals showing organ loads <1 TCID50 equivalent/mg
tissue. rVSV-ZEBOV-GP-NiVN vaccinated animals showed a greater than 2-log
reduction in viral organ loads compared to the rVSV-ZEBOV-GP vaccinated controls. In
order to confirm that the positive immunohistochemistry described below (Figure	
  5-‐4)
represents replication of the challenge virus (NiV) rather than N expressed by the vaccine
vector (rVSV-ZEBOV-GP-NiVN), we performed a VSV N-specific qRT-PCR assay. No
VSV N RNA could be detected in lung tissue of the rVSV-ZEBOV-GP-NiVN vaccinated
animals. NiV isolation was only successful from control animals (rVSV-ZEBOV-GP
group).
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Figure	
  5-‐3:	
  Vaccination reduces Nipah virus load in tissues.	
  	
  
Tissues (brain, spleen, lung) were collected in RLT buffer from four animals per group
on day 5 after challenge and homogenized prior to total RNA extraction. Quantitative
RT-PCR using an N-specific primer and probe set was used to determine TCID50
equivalents by extrapolating from a standard curve from a NiV seed stock of known titer.
Individual animals are represented by dots and horizontal lines represent the mean, error
bars indicate standard error of the mean (SEM).
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Figure	
  5-‐4:	
  Vaccination reduces Nipah virus pathology.	
  	
  
Four hamsters per group were euthanized 5 days post challenge and lung sections were
stained with H&E (top panel) for histopathology evaluation and IHC targeting NiV N
protein for virus replication (bottom panel). Infected lungs showed thickening of the
alveolar septae (arrows) by congestion, fibrin, edema, and small numbers of
inflammatory cells. Alveolar spaces are filled with fibrin, edema, and inflammatory cells
(asterisk). Inset in IHC panel demonstrates positive staining of NiV N-antigen (arrow
heads). Images were taken at a magnification of 200× and inset at 1000×.
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Staining for histological analysis was performed on lung tissue derived from the
same 4 animals euthanized 5 days post challenge. All rVSV-ZEBOV-GP vaccinated
control animals developed multifocal interstitial pneumonia characterized by thickening
of the alveolar septae by small to moderate numbers of macrophages, fewer neutrophils,
congestion, fibrin and edema (Figure	
  5-‐4). Occasionally, small numbers of inflammatory
cells, fibrin and edema filled the adjacent alveolar spaces. There was also multifocal
pleural mesothelial hyperplasia. Alveolar and arteriolar endothelial cells and pulmonary
arteriolar smooth muscle cells demonstrated diffuse viral antigen by IHC staining (Figure	
  
5-‐4). Most animals (three out of four) in the partially protected rVSV-ZEBOV-GP-NiVN
group developed pneumonia similar to that found in controls. These hamsters had rare
and weak multifocal viral antigen staining, primarily within mononuclear cells in areas of
pneumonia. All animals in the completely protected groups (rVSV-ZEBOV-GP-NiVF
and rVSV-ZEBOV-GP-NiVG) showed no lesions and were negative for viral antigen by
IHC staining (Figure	
  5-‐4).
Passive serum transfer protects naïve animals from Nipah virus infection
To test whether antibodies elicited by the rVSV vectors alone can afford
protection against NiV challenge, we performed a passive transfer experiment. Groups of
18 hamsters were vaccinated with 105 PFU i.p. of one of the rVSV vectors. After 28 days,
sera were collected and pooled for each group. Pooled sera from rVSV-ZEBOV-GPNiVF and rVSV-ZEBOV-GP-NiVG had neutralization titers of 200 and 400,
respectively, whereas sera collected from the rVSV-ZEBOV-GP and rVSV-ZEBOV-GPNiVN vaccinated groups were negative. Groups of six naïve hamsters were administered
i.p. 1 mL of pooled serum the day prior to and the day following NiV challenge (1000
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LD50). All animals, except one, that received serum without neutralizing activity (rVSVZEBOV-GP and rVSV-ZEBOV-GP-NiVN) had to be euthanized according to protocol
(Figure	
  5-‐5). All animals that received serum displaying neutralizing activity (rVSVZEBOV-GP-NiVF- or rVSV-ZEBOV-GP-NiVG) were completely protected from NiV
challenge with no signs of disease.
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Figure	
  5-‐5:	
  Passive serum transfer protects naïve hamsters from Nipah virus challenge.	
  
Serum	
  was	
  collected	
  from	
  groups	
  of	
  18	
  hamsters	
  28	
  days	
  after	
  vaccination	
  
with	
  105	
  PFU	
  of	
  the	
  specific	
  vaccine	
  vectors.	
  One	
  day	
  prior	
  to,	
  and	
  1	
  day	
  post	
  
challenge	
  with	
  1000	
  LD50	
  of	
  NiV,	
  groups	
  of	
  six	
  naïve	
  hamsters	
  were	
  given	
  1	
  mL	
  
of	
  sera	
  from	
  immunized	
  animals	
  and	
  monitored	
  for	
  42	
  days	
  for	
  signs	
  of	
  
disease.	
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Discussion
Over the past decade, multiple distinct NiV vaccine approaches have been
developed and evaluated in different animal models, including DNA vaccines, subunit
vaccines (virus-like particles, soluble G protein), replication-deficient vectors as well as
replication-competent vectors. Several of these approaches have only been evaluated for
their ability to elicit immune responses, whereas others have been used to evaluate
protective efficacy against NiV challenge in different animal models (49, 54, 99, 105–
110, 112, 113, 115, 116, 155, 156).
With the exception of three recent studies, all vaccine approaches thus far have
required a boosting immunization scheme for immunogenicity and/or efficacy and are
therefor less likely to be useful for ring vaccination approaches in an outbreak situation.
The three new studies include an adenovirus-associated virus vector expressing NiV G
(108), replication-incompetent VSV pseudotypes expressing NiV G or F proteins (113)
and a VSV virion with F and G that can undergo a single round of replication that was
produced by co-infection of two VSV pseudotypes , one expressing F and one expressing
G (114). The adenovirus-associated virus vector approach used relatively high vaccine
doses, and the VSV approaches are based on replication-deficient pseudotype particles
produced by plasmid transfections, both of which may be challenging in regards to
vaccine production.
Our goal was to develop a fast-acting, single-dose NiV vaccine suitable for use as
a ring vaccination approach during outbreaks as they currently occur in Bangladesh. We
chose live-attenuated rVSV vectors as our platform due to their ease of genetic
modification and their subsequent efficient and cost-effective manufacturing. We
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preferred a replication-competent vaccine as those generally provide better durability
when compared to a replication-incompetent vaccine approaches, eliciting faster and
more effective innate and adaptive immune responses (166). Replication-competent
vaccine approaches, however, are commonly associated with safety concerns, but all of
our previous vaccine work using the rVSV platform, including immunization of several
immune-compromised animal species, has assigned this approach a good safety record
(159, 167). Noteworthy, a live-attenuated rVSV-based vaccine vector was approved for
use in a human laboratory exposure to Ebola virus (168). Among commonly used
replicating vaccine vectors, VSV provides advantages over similar platforms, such as the
limited pre-existing immunity against VSV in the human population and the only rare
and mild human disease caused by VSV, which is largely an animal pathogen (169, 170).
To further limit VSV immunity and pathogenicity, we removed VSV-G, the major target
for neutralizing antibodies and a key VSV virulence factor (170). VSV-G was replaced in
the vaccine vector by ZEBOV-GP to overcome the lack of a functional surface protein
for virus entry. Virus entry cannot be achieved by any of the chosen NiV antigens,
because henipavirus cell entry is dependent on the presence of both G and F proteins
(149). The ZEBOV-GP was particularly chosen for its known targeting of important
immune cells, such as mononuclear phagocytotic and antigen presenting cells (160, 165,
171). Targeting of these cells allows for their strong stimulation and better antigen
presentation by MHC class I and II pathways, and thus leads to more potent innate and
adaptive immune responses (172, 173).
In order to characterize the mechanism of protection afforded by the rVSV-based
vaccine vectors, we examined the importance of the humoral immune responses.
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Previously it has been demonstrated that protection against NiV challenge can be
afforded by passive serum transfer that contains neutralizing antibodies (99).
Additionally, m102.4, a human neutralizing monoclonal antibody, can protect against
NiV and Hendra virus in several animal models (54, 103). The rVSV vaccine vectors
expressing NiV F or G both induced glycoprotein-specific antibody responses that
conferred complete protection against NiV challenge in a serum transfer study.
Neutralizing antibody responses are most likely key for protection, as serum transfer of
N-specific antibodies did not show any protective effect, even though the role of nonneutralizing glycoprotein-specific antibodies for protection cannot be excluded. VSV is
known to also elicit strong cellular immune responses (166, 174, 175). The role of
cellular immune responses mediated through rVSV vectors is supported here by the
partial protection achieved through vaccination with the rVSV vector expressing NiV N
as well as the lack of protection in serum transfer experiments using sera with N-specific
non-neutralizing antibodies. Therefore, these new rVSV vectors might be stronger
vaccine candidates than vaccine platforms that more selectively trigger humoral immune
responses, such as subunit protein vaccines (109, 110, 155).
Conclusions
Here we describe a vaccine approach and mechanism of protection that could be
used to control NiV infections and spread in outbreak situation if used in a ring
vaccination approach. Recent outbreaks have involved increased human-to-human
transmission events, most often seen in family members or healthcare workers (67). Due
to the ease in identifying high-risk individuals, those in close contact with patients, fastacting, single-dose vaccines, like the rVSV vectors here, would be advantageous for
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targeted use during outbreaks over vaccines that need multiple injections and thus require
more time between vaccination and protection. Another advantage of replicationcompetent rVSVs has been its efficacy upon use peri-exposure, allowing for
simultaneous vaccination and treatment in outbreak situations (159, 160, 165, 176, 177).
Future studies are aimed to assess time to immunity and peri-exposure treatment efficacy
of these new rVSV NiV vectors as well as efficacy studies in a second animal model to
fulfill FDA requirements for licensing.
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CHAPTER 6 GENERAL DISCUSSION AND CONCLUSIONS
Nipah virus is a zoonotic pathogen that causes disease in humans in Asia. The
initial outbreak of Nipah virus originated in Malaysia and caused over 100 human deaths
as well as the culling of over 1 million pigs (26). Subsequent outbreaks have been
localized to Bangladesh and India causing almost annual outbreaks. In the case of Nipah
and Hendra viruses infection, there is no known treatment, infection is often fatal (~70%
CFR), and may cause relapsing encephalitis (27, 78). Like many other emerging
infectious diseases, Nipah virus emerged from a spill-over event from reservoir (bats) to
domestic animals/livestock (pigs), followed by humans infection (sometimes human-tohuman transmission). Today, with the increase in land use causing human encroachment
and deforestation the interface between human/wildlife is increasing leading to the
increase prevalence of new human pathogens (179–181). Factors like human bushmeat
consumption, climate change, movement of animal species, increased population and
shrinking wilderness habitat all play a role in increased interaction between wildlife and
humans (182–185). Over the years, examples of increased spillover has been seen with
the emergence of human immunodeficiency virus (HIV), chikungunya virus, influenza,
and Middle East respiratory syndrome coronavirus to name a few (186). Research should
focus on this interface, studying emerging and reemerging pathogens in a one-health
approach including both human and veterinary studies.
Focusing on multidisciplinary studies during the Nipah outbreak in Malaysia, we
see effects on human health, livestock health, and damage to the economy all caused by
the outbreak. Nipah virus was found to be a bat-borne pathogen that spilled over into pigs
in Malaysia (32, 34). Once the connection between bats-pigs-humans was made, action
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was taken to reduced interactions between species; this led to the end of the outbreak and
spread of the virus (26). However, this was after the virus spread to Singapore and caused
more than 250 cases, and left many with relapsing encephalitis (76). Beside the human
impact, the outbreak halted animal trade, closed many farms, and lead to the culling of
over 1 million pigs, thus causing great economic loss. The virus reemerged in Bangladesh
in 2001 and causes small outbreaks there and in neighboring India on an almost yearly
basis. These outbreaks are thought to be caused by human-bat interactions and often are
linked to the harvesting and drinking of date palm sap (44, 131). After this connection
was made steps were made to reduce bat-human contact and bat-date palm sap
interactions; the effects are still under review but appear to be reducing cases (41, 187).
Another factor causing concern over Nipah virus is the large host range of the reservoir
species and the detection of Nipah-like sequences in bats in Thailand, Africa, and
Australia further emphasizing the importance of Nipah virus and strengthen the need to
study this zoonotic pathogen (2, 38–40, 68, 188). The study of this virus has led to
reduced infectious, however outbreaks still occur and further research into Nipah virus
needs to be completed to further understand viral infection, develop therapies or vaccines,
as well as manage future outbreaks more efficiently. To contribute to completing these
goals, we 1) studied variations of the virus strains, comparing them in animals; 2) better
defined pathology in important cell types; and 3) developed and tested vaccine candidates
for future use during outbreaks.
Specifically we studied the outcome of infection with both Nipah strains in cell
culture and in the hamster model focusing on pathogenesis and the host immune
response. The strains were isolated from geographically and temporary separate
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outbreaks(28, 125). Epidemiologic data and disease progression during outbreaks differs
between strains. The current understanding of Nipah virus pathogenesis has come from
human autopsies and experimental work with the Malaysian strain of Nipah virus. We
infected hamster cells with both strains and found that Nipah Malaysia replicated faster
and had more cytopathic effect (CPE) and syncytia formation compared to the
Bangladesh strain. In the hamster model there was also a slight difference between
strains. Overall there is a delay (about 2 days) in Nipah Bangladesh disease progression,
including time to death, virus replication, pathology and immune response, compared to
Malaysia infected animals. Overall infection with either strain resulted in similar disease
and outcome in hamsters. This data hints that discrepancies in human life style, cultural
differences, and quality of health care between the two countries could account for the
differences in epidemiology reported rather than the differences in sequence (73, 189).
We also studied infection in the microvasculature, a major target of Nipah virus
infection. Specifically, we focused on studying Nipah infection in endothelial cells (EC)
and smooth muscle cells (SMC) using both animal models and primary human cell
culture. We found that in hamster and African green monkey tissue Nipah virus antigen
was detected in EC lining small vessels in the lung as well as the surrounding SMC. EC
positive for Nipah virus antigen often showed signs of pathogenesis including syncytia
formation, while SMC were infected but showed no negative effect from infection.
Similarly to in vivo data, studies in primary human EC and SMC showed permissibility to
infection and only CPE in EC. Further experiments showed that only a small fraction of
SMC were infected in culture even though viral titers produced were high. This led us to
hypothesize that entry into the cell and/ or spread to neighboring cells could be the
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limiting factor/s in SMC infection. In testing the ability of SMC to fuse we found that
infected SMC could fuse with non-infected EC, thus proving the ability of SMC to form
syncytia after infection. To test entry as the limiting factor we analyzed receptor
expression and found that SMC express little to no ephrin B2/B3 on the surface. The
exact mechanism of viral entry in SMC need to be further studied; this data suggests that
cells could become infected by other means, be it macropinocytosis or a second receptor.
After studying pathogenesis, we focused on creating a countermeasure that would
protect from infection/disease. We created recombinant vesicular stomatitis virus based
vaccines expressing Nipah virus antigens (glycoprotein, fusion protein, or nucleoprotein)
and tested their efficacy in the hamster model. The glycoprotein and fusion protein
group’s showed no signs of disease or weight loss after infection and were completely
protected from disease. Nucleoprotein vaccinated animals were partially protected with 2
out of 6 showing no clinical disease. As expected, control animals showed signs of
disease and succumb to infection. In tissues we found that vaccination against Nipah
reduced viral replication and antigen detection compared to control. This data supported
the efficacy of our vaccines. In order to better understand the mechanisms of protection
we did a passive transfer into naïve animals, which provided complete protection in
vaccines that elicited neutralizing antibodies (F and G). Taken together this data suggest
that neutralizing antibodies are enough to provide protection but that other cellular
responses add to protection. This study showed that our vaccine was efficacious and that
the VSV backbone is a strong inducer of antibodies and cellular responses that strengthen
protection.
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In conclusion, this work further elucidated pathology caused by Nipah virus
infection and developed and testing of a potential vaccine candidate. We were the first to
describe experimental infection of animals with Nipah Bangladesh as well as directly
compare the strains under an experimental setting. Our work set the ground work for
future experiments with the Bangladesh strain including further strain comparison in
other animal models (190), transmission studies (51), and vaccine testing. Before this
work little was known about Nipah infection in smooth muscle cells. Previous works
have documented positive antigen staining in these cells but no work had yet studied their
role in pathology and viral replication. Our work fills this gap of knowledge as well as
leads to some interesting questions for further study. In this work we also describe a
potent single dose vaccine that fully protects hamsters. This vaccine differs from
previously published vaccines by eliciting a fast strong immune response after a single
dose. Together our study adds to the fields understanding of Nipah virus pathology as
well as proposes a possible vaccine candidate for use against disease, contributing to
future management and treatment of outbreaks.
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